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Immune checkpoint molecules function as a system of checks and balances that 
enhance or inhibit immune responses to infectious agents, foreign tissues, and cancer-
ous cells. Immunotherapies that target immune checkpoint molecules, particularly the 
inhibitory molecules programmed cell death 1 and cytotoxic T-lymphocyte-associated 
protein 4 (CTLA-4), have revolutionized human oncology in recent years, yet little is 
known about these key immune signaling molecules in species other than primates 
and rodents. The Tasmanian devil facial tumor disease is caused by transmissible 
cancers that have resulted in a massive decline in the wild Tasmanian devil popula-
tion. We have recently demonstrated that the inhibitory checkpoint molecule PD-L1 is 
upregulated on Tasmanian devil (Sarcophilus harrisii) facial tumor cells in response to 
the interferon-gamma cytokine. As this could play a role in immune evasion by tumor 
cells, we performed a thorough comparative analysis of checkpoint molecule protein 
sequences among Tasmanian devils and eight other species. We report that many of 
the key signaling motifs and ligand-binding sites in the checkpoint molecules are highly 
conserved across the estimated 162 million years of evolution since the last common 
ancestor of placental and non-placental mammals. Specifically, we discovered that the 
CTLA-4 (MYPPPY) ligand-binding motif and the CTLA-4 (GVYVKM) inhibitory domain 
are completely conserved across all nine species used in our comparative analysis, 
suggesting that the function of CTLA-4 is likely conserved in these species. We also 
found that cysteine residues for intra- and intermolecular disulfide bonds were also 
highly conserved. For instance, all 20 cysteine residues involved in disulfide bonds 
in the human 4-1BB molecule were also present in devil 4-1BB. Although many key 
sequences were conserved, we have also identified immunoreceptor tyrosine-based 
inhibitory motifs (ITIMs) and immunoreceptor tyrosine-based switch motifs (ITSMs) in 
genes and protein domains that have not been previously reported in any species. 
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This checkpoint molecule analysis and review of salient features for each of 
the molecules presented here can serve as road map for the development of a 
Tasmanian devil facial tumor disease immunotherapy. Finally, the strategies can 
be used as a guide for veterinarians, ecologists, and other researchers willing to 
venture into the nascent field of wild immunology.
Keywords: devil, transmissible tumor, cosignaling immunotherapy, checkpoint blockade, wild immunity, 
allograft, transplant rejection, evolution
INTRODUCTION
The immune system plays a vital role in protecting an animal from 
pathogens and cancers through various immunosurveillance and 
effector mechanisms. The pathogenic cells and/or microbes that 
escape or neutralize host immunity produce more surviving 
descendants that are in turn more effective at evading immune 
responses. The architecture of the vertebrate immune system and 
the mechanisms by which immune responses are regulated are 
the result of this long and complex evolutionary arms race. This 
arms race drives continuous evolution of the immune system, but 
many defenses have persisted throughout this long-history and 
are conserved across speciation events.
Immune checkpoint molecules function as a complex system 
of checks and balances that promote or inhibit immune responses. 
Checkpoint molecules likely evolved to precisely balance the need 
to control pathogens and cancer with the need to maintain toler-
ance to healthy tissues and the microbiota (Figure 1). However, 
the delicate balance of tolerance and immunity can be upset by 
pathogens and tumor cells that subvert inhibitory pathways to 
evade host immune defenses.
Checkpoint molecule immunotherapy has recently surged 
onto the world stage, but this field emerged over three decades of 
basic immunobiological research, primarily focused on T cells. 
In general, activation of T  cells requires signaling through the 
T cell receptor (TCR) (signal 1) and cosignaling through CD28 
(signal 2), a constitutively expressed disulfide-linked homodimer 
on the surface of naïve T cells (1–3). Signal one is derived from 
interactions of the TCR with its cognate major histocompatibility 
complex (MHC) peptide-complex (4). Signal two is derived from 
CD28 binding with either CD80 (B7-1) or CD86 (B7-2), primarily 
expressed by dendritic cells (DCs) and other antigen-presenting 
cells (APCs), such as macrophages and B cells. TCR signaling in 
the absence of CD28 cosignaling can result in T cell anergy (5). 
Following activation of T cells, the inhibitory molecule cytotoxic 
T-lymphocyte-associated protein 4 (CTLA-4) is upregulated on 
the cell surface (6). CTLA-4 has a higher affinity for both CD80 
and CD86 than does CD28 (7–9), and thus CD28 cosignaling is 
suppressed by CTLA-4 outcompeting CD28 for CD80 and CD86 
binding. The result is a downregulation of the T cell response and 
loss of T cell function.
Immunotherapies targeting the CTLA-4 checkpoint molecule 
have opened new doors in the realm of human oncology. Two 
antagonistic anti-CTLA-4 mAbs, ipilimumab (IgG1 isotype) and 
tremelimumab (IgG2 isotype), that block interactions between 
CTLA-4 and its coreceptors CD80 and CD86 have been clinically 
approved for advanced stage cancers. The exact mechanisms 
by which anti-CTLA-4 works are not completely understood. 
Accumulating evidence suggests that anti-CTLA-4 works primar-
ily in the secondary lymphoid organs by releasing pre-existing 
T cells from inhibitory signaling to target tumor neoantigens and 
by depleting Tregs in the tumor microenvironment (10, 11).
Despite the promising early results of anti-CTLA-4 mAb 
monotherapy in human clinical trials, objective response rates 
remained low in most cases. Improvements have been observed 
when anti-CTLA-4 was paired with other treatments, such as the 
chemotherapy drug dacarbazine (12). However, the most prom-
ising outcomes have been observed when anti-CTLA-4 mAb is 
paired with blockade of the programmed cell death 1 (PDCD1, 
PD-1) protein (13–15).
Anti-PD-1 has been the most successful checkpoint blocking 
monoclonal antibody in treating human cancer, in monothera-
pies or in combination therapies. Anti-CTLA-4 and anti-PD-1 
combination therapies have achieved unprecedented objective 
response rates of nearly 60% in patients with stage III and IV 
melanoma (14, 15). PD-1 immunotherapies have focused largely 
on stimulating T cell antitumor responses by blocking binding of 
PD-1 to its ligands PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, 
CD273). PD-1 blockade abrogates the inhibitory effects of PD-1 
ligation mediated by the immunoreceptor tyrosine-based inhibi-
tory motif (ITIM) and immunoreceptor tyrosine-based switch 
motif (ITSM) in the PD-1 cytoplasmic tail (16–18). In addition 
to blocking the inhibitory effects of PD-1, blockade of PD-L1 
ligation can render tumor cells less resistant to apoptosis (19). 
PD-L1 and PD-L2 proteins are largely absent in normal tissues, 
but PD-L1 expression is elevated in more than 20 types of human 
cancer [reviewed in Ref. (20)]. Furthermore, many cancers and 
healthy cells upregulate PD-L1 expression in response to inflam-
matory cytokines, such as interferon-gamma (IFN-γ).
In humans, PD-L1 expression in the tumor microenvironment 
is associated with an inhibited T  cell antitumor response and 
reduced patient survival [reviewed in Ref. (20)]. PD-L1 expres-
sion in the tumor microenvironment plays an important role in 
shaping a dysfunctional immune response through reprogram-
ming of APCs, regulatory T cells, and expression of inhibitory 
molecules. PD-L2 is not routinely detected on cancer cells, but 
is commonly expressed by DCs, which led to the alternative 
name of B7-DC (21). A second coreceptor for PD-L2, repulsive 
guidance molecule b, has recently been discovered and has been 
implicated in respiratory immune tolerance (22).
Orthologs of CTLA-4 and PD-1 and their coreceptors have 
been found in nearly all mammals and birds studied to date 
(23, 24), but comparatively little is known about the potential for 
checkpoint molecule immunotherapy in the field of veterinary 
FIGURE 1 | Generalized schematic of checkpoint molecule structure and expression, and the balance between stimulatory and inhibitory signaling. 
(A) The net balance of inhibitory (−, blue) and stimulatory (+, red) signals regulates antitumor immune responses. The tumor microenvironment is dynamic and is 
molded by inhibitory and stimulatory signals both in the microenvironment and distant tissues (i.e., lymph nodes). Development of cytotoxic effector T cells and 
NK cells is regulated by the balance between inhibitory and stimulatory signaling, including both receptor:coreceptor interactions and cytokines. Both receptor and 
cytokine expression are also regulated by that balance of stimulatory and inhibitory signals, creating feedback loops that evolved to eliminate pathogens and cancer 
while simultaneously limiting collateral damage. (B) Expanded view of potential receptor:coreceptor interactions between T cells, NK cells, antigen-presenting cells 
(APCs), and tumor cells. The graphic here demonstrates some of the best characterized pathways, with a particular focus on T cell and NK cell interactions with 
tumor cells and APCs. Note that many of the ligands depicted here are expressed on several cell types and interactions with coreceptors and ligands can result in 
different functional outcomes depending on the cell types and microenvironment. For example, CD47 is expressed on all cells, but the pathway of primary interest 
for transmissible tumors is for the ability of tumor cell-expressed CD47 to inhibit phagocytosis via binding to SIRP-α on APCs. In addition to binding to SIRP-α, 
CD47 also binds to SIRP-β, SIRP-γ, THBS1, and THBS2, but we have only shown the CD47:SIRP-α interaction here to keep the figure relatively simple. Both 
V-domain Ig suppressor of T cell activation (VISTA) and B7-H4 have unknown coreceptors (labeled as “?” in the diagram) whose function has been studied  
using fusion proteins, but the genes for the coreceptors have yet to be identified.
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medicine or in the realm of wildlife disease. Initial investigations 
into the function of CTLA-4, PD-1, and PD-L1 have been under-
taken for canids (25–30), felids (31), and bovids (32–35), and 
results suggest that the CTLA-4 and PD-1/PD-L1 expression pat-
terns and function are similar among these placental mammals.
An area where checkpoint molecule immunology could make 
a wildlife conservation impact is in the unusual cases of trans-
missible tumors. These transmissible tumors represent a unique 
immunological enigma because they can also simultaneously be 
considered infections and allografts. Disease progression, trans-
mission, and the host immune response can only be properly 
understood when these tumors are considered in this complex 
tumor–infection–allograft context.
The Tasmanian devil facial tumor (DFT) was identified in 
1996, and in 2006 the etiologic agent was found to be cancer 
cells that are transmitted between biting devils (36, 37). At the 
time of discovery, the only other known naturally transmis-
sible tumors were the canine (Canis lupus familiaris) transmis-
sible venereal tumor (38, 39) and a set of related Syrian hamster 
(Mesocricetus auratus) transmissible sarcomas (40, 41). In recent 
years, additional transmissible tumors have been discovered in 
soft-shell clams and other bivalves (42, 43). Remarkably, in 
2015, we discovered a second transmissible devil facial tumor 
(DFT2) in wild Tasmanian devils (referred to as devils hereafter) 
that is genetically distinct from the original devil facial tumor 
(DFT1) (44).
Previous research has shown that reduced cell surface expres-
sion of MHC-I plays a major role in DFT1 immune evasion, but 
that IFN-γ can upregulate beta-2 microglobulin (β2m), ergo 
MHC-I expression (45). This immune evasion mechanism has 
been described in many types of cancer, and begs the question as 
to why the MHC-negative DFT cells are not targeted by NK cells 
in line with the “missing-self ” hypothesis (46). Studies have dem-
onstrated the NK cell genes are present in devils and that devil 
NK-like cells can mount an antitumor response (47–49). Despite 
the complimentary mechanisms of cytotoxic T cells and NK cells, 
immune responses against the DFTs are rare (50), suggesting that 
additional immune evasion mechanisms could be present.
Recent vaccination efforts have demonstrated that IFN-
γ-stimulated DFT  cells can induce antitumor responses and 
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tumor regressions in a subset of cases (51). However, initial 
forays into checkpoint molecule immunology of the DFT 
disease has shown that both DFT1 and DFT2 also upregulate 
PD-L1 upon exposure to IFN-γ (52), suggesting that anti-DFT 
immunotherapies could be enhanced by neutralizing the PD-1 
inhibitory pathway. Given that the immune system has many 
redundant mechanisms for identifying and killing infectious 
agents and tumors, it is likely that the transmissible tumors 
employ additional methods beyond MHC-I downregulation 
and PD-L1 upregulation for evading host immune defenses and 
facilitating tumor transmission.
We have performed a comparative analysis of the protein 
sequences of key immune checkpoint molecules in the three 
mammalian species known to harbor naturally transmissible 
cancers (devils, dogs, and hamsters) and six other mammals 
(Table  1). We have not included the analysis of PD-1, PD-L1, 
and PD-L2 here, as we have previously published this informa-
tion (52). Understanding the broad role of checkpoint molecules 
in these complex diseases has the potential to shed light on 
fundamental aspects of immune evasion, transplant tolerance 
and rejection, and infectious disease; this is logically relevant to 
both human and veterinary medicine. This checkpoint molecule 
analysis and review of salient features for each of the molecules 
presented here can serve as road map for the development of a 
DFT immunotherapy and as a guide for veterinarians, ecologists, 
and other researchers willing to venture into the nascent field of 
wild immunology.
MATERIALS AND METHODS
Species
We included nine species in our comparative analysis of check-
point molecules. Humans and mice were included because 
checkpoint molecules have been best characterized in these 
species. We have included the little brown bat (Myotis lucifugus) 
in our comparative analyses because like devils, the species has 
recently undergone a dramatic population crash due to disease, 
and understanding bat immunology has become increasingly 
important due to the ability of bats to serve as reservoirs for 
viral pathogens (e.g., rabies, ebola, SARS). We have also included 
cats (Felis catus) and cattle (Bos taurus) due to their widespread 
distribution as important domestic animals. See Table 1 for a full 
list of species names and abbreviations used.
Sequences
DNA sequences for all genes analyzed here were collected from 
GenBank and Ensembl and reference numbers for all sequences 
are available in Table S1 in Supplementary Material (53). All 
reference sequences current as of 30-Jan-2017, including the 
most current devil genome (Devil_ref v7.0). The complete 
coding sequence for the V-domain Ig suppressor of T cell activa-
tion (VISTA), CD47, and TIM-3 genes was not available from 
either GenBank or Ensembl, so sequences were obtained from 
a de novo transcriptome assembly (Table S2 in Supplementary 
Material) described below. The full coding sequences were sub-
mitted to GenBank with accession numbers: KY856749 (VISTA), 
KY856750 (CD47), and KY856751 (TIM-3). Where more than 
one sequence was present we generally chose GenBank transcript 
X1, unless preliminary alignments suggested that an alternative 
transcript was a better match to the other species used here. 
BLAST was used to find additional potential matching sequences 
for each gene (54). The available reference sequences for several 
genes that have not been characterized in their respective species 
contained elongated 5′ regions upstream of the likely start codon, 
so we manually truncated the amino acid sequences depicted in 
the alignment figures for the following genes: opossum CD80 and 
VISTA, bat CD86 and CD47, and hamster B7-H4.
RNA Sequencing (RNA-seq)
RNA sequencing data were generated as part of a previous 
study (55). Briefly, RNA was extracted from peripheral blood 
mononuclear cells (PBMCs) obtained from two disease-free 
devils. Illumina single-end 100  bp RNA-seq was conducted by 
the Australian Genome Research Facility. Sequencing generated 
82,609,965 and 82,254,904 sequences, respectively. Fastq reads 
for each sample were assessed with FastQC version 0.11.5 (56), 
with both samples having acceptable per base sequence quality 
measurements. Genome-independent de novo assembly of the 
RNA-seq data was completed using the Trinity platform ver-
sion 2.2.0 (57, 58) with default settings applied. This generated 
a reference transcriptome of assembled transcripts collectively 
from the two samples. The de novo transcriptome assembly was 
queried with BLASTN version 2.4.0+ (59) with coding sequences 
of the target genes obtained from Ensembl (53), database version 
87.7, and UCSC Genome Browser (60). This identified transcript 
sequences from the assembled transcriptome of our target genes 
to use in comparative alignment analysis. Further information 
on this analysis is detailed in the Data Sheet S1 in Supplementary 
Material. Access to the raw fastq sequence data, Trinity assembled 
de novo transcriptome, and BLASTN results are detailed in the 
Data Sheet S1 in Supplementary Material.
Protein Sequence Alignments
Protein sequences were aligned with CLC sequence viewer 
using a progressive alignment algorithm with gap open cost = 5, 
gap extension cost = 1, end gap cost =  free (61, 62). Pairwise 
protein sequence identities between devils and other species 
were determined using the default parameters on the Clustal 
Omega web server (63). We used the RasMol coloring scheme 
to highlight traditional amino acid properties in all sequence 
TABLE 1 | Names and identifiers for species used in comparative 
sequence analysis.
# Short name Common name Species name Taxid
1 Devil Tasmanian devil Sarcophilus harrisii 9305
2 Opossum Gray short-tailed opossum Monodelphis domestica 13616
3 Bat Little brown bat Myotis lucifugus 59463
4 Cat Domestic cat Felis catus 9685
5 Cattle Cattle Bos taurus 9913
6 Dog Domestic dog Canis familiaris 9615
7 Hamster Golden hamster Mesocricetus auratus 10036
8 Human Human Homo sapiens 9606
9 Mouse House mouse Mus musculus 10090
FIGURE 2 | Alignment of cytotoxic T-lymphocyte-associated protein 4 reference genes for nine species. The predicted signal peptides (SigP), extracellular 
domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide 
bonds. MYPPPY indicates the conserved CD80- and CD86-binding site. GVYVKM indicates a conserved cytoplasmic inhibitory domain and TRAF indicates a 
putative TRAF6-binding site. The black bars graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino  
acid sequence identity between devils and other species is shown in the bottom right corner of the alignment.
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alignments, which aids in interpretation of amino differences 
across species (64).
Analysis of Protein Sequences
All sequences were analyzed using the ExPASy server ProtParam 
tool to predict molecular weight and extinction coefficients (65). 
The eukaryotic linear motif (ELM) tool was used to predict key 
signaling motifs (66). The Simple Modular Architecture Research 
Tool (SMART) and the Phobius web server (67) were used to pre-
dict Ig-like domains and membrane topology (68). SignalP was 
used to confirm predicted signal peptides (69). Disulfide bonds 
and other unique features of each protein that were annotated 
on UniProt (70) were used to predict features in devil protein 
sequences.
RESULTS
The CTLA-4 and CD28 pathways are perhaps the most studied 
of the checkpoint molecules, but functional testing in species 
other than mice and humans is limited. A battery of tools (i.e., 
TABLE 2 | Protein sequence percent identity between checkpoint molecules in devils and eight other species.
Species Cytotoxic T-lymphocyte-
associated protein 4
CD28 CD80 CD86 V-domain Ig 
suppressor of 
T cell activation
4-1BB CD47 SIRP-α CD200 TIM-3 Lymphocyte 
activation 
gene 3
B7-H4
Opossum 85.7 72.4 55.2 49.2 73.7 75.5 87.1 69.2 65.7 52.7 72.5 93.9
Bat 68.5 53.9 33.9 35.9 65.6 48.0 54.2 56.3 54.7 43.0 48.7 84.1
Cat 68.9 55.9 36.9 35.1 64.8 51.2 65.2 56.6 56.3 43.3 46.3 85.9
Cattle 66.1 56.0 36.3 35.9 65.8 50.8 67.4 55.3 53.2 42.1 50.6 85.9
Dog 68.9 56.4 35.0 37.8 63.2 53.8 67.1 56.7 52.8 43.1 43.0 87.7
Hamster 65.3 57.4 33.6 32.4 60.0 43.4 64.2 52.7 51.7 44.4 48.7 79.6
Human 65.8 56.2 35.5 36.6 64.9 52.2 66.8 55.8 56.2 43.2 51.9 87.0
Mouse 63.1 54.4 35.7 35.0 61.9 44.2 64.5 53.1 53.2 42.3 50.0 81.9
Percent identity was calculated by Clustal 2.1 algorithm.
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recombinant proteins, monoclonal antibodies) and time are 
needed for proper testing of checkpoint molecule function, but 
much information and insight into function can be gained by 
analysis of protein sequences. For each molecule analyzed, we 
begin with a description of the general structure (i.e., Ig-like 
superfamily domains) and proceed to more nuanced details. This 
provides insight into potential functions of the molecules and can 
provide direction for designing critical experiments prior to the 
embarking on the time-consuming process of empirical testing of 
molecular function. See Table S3 in Supplementary Material for 
details of checkpoint molecule structure.
CTLA-4, CD28, CD80, and CD86
Devil CTLA-4 and CD28 are predicted to be 25 and 28  kDa, 
respectively, type-I transmembrane proteins with a single Ig-like 
V-type extracellular domain (ECD) (Figure 1). Protein sequence 
identity for CTLA-4 between devils and opossums was 86% and 
ranged from 63 to 69% between devils and placental mammals 
(Figure  2; Table  2). Percent identity for CD28 among species 
was lower than for CTLA-4, with 72% between devils and opos-
sums and ranging from 54 to 57% between devils and placental 
mammals (Figure  3). Devil CTLA-4 had approximately 29% 
amino acid sequence identity with CD28. The CTLA-4 and CD28 
coreceptors CD80 and CD86 are predicted to both be 35  kDa 
type-I transmembrane proteins that contain Ig-like V-type and 
an Ig-like C2-type domains. Devil CD80 and CD86 share only 
21% sequence identity with each other, and the identity across 
the species analyzed here ranges from 34 to 55% and 32–49% 
for CD80 (Figure  4; Table  2) and CD86 (Figure  5; Table  2), 
respectively; the percent identity for CD80 and CD86 across spe-
cies is the lowest of any of the checkpoint molecules compared 
here. All intra- and intermolecular disulfide bonds that have been 
identified in humans for CTLA-4, CD28, CD80, and CD86 are 
likely present in all the orthologs analyzed here, as we observed 
100% conservation of cysteine residues at these sites in all species 
tested (Figures 2–5).
Key Ligand-Binding Regions Conserved in Devil 
CTLA-4 and CD28
Our analysis shows that devil CTLA-4 and CD28 both contain 
the MYPPPY motif that is necessary for binding of CTLA-4 and 
CD28 to CD80 and CD86 in humans and mice (Figures 2 and 3) 
(7). Of the 18 combined CTLA-4 and CD28 sequences aligned 
here, only cattle CD28 did not contain the CD28MYPPPY motif (71); 
cattle had a CD28LYPPPY sequence, which matches the CD28LYPPPY 
and CTLA-4LYPPPY that has been previously reported in pigs (Sus 
scrofa) and decreases affinity of porcine CTLA-4 for human 
CD80 and CD86 (35, 72). Additionally, all species also contain 
the CTLAGVYVKM inhibitory domain. Except for bats, all species 
also contain the key CD28SDYMNM and CD28PYAP motifs are critical 
for intracellular signaling that promotes T cell proliferation and 
survival via the CD28–PI3K–AKT [reviewed in Ref. (73)]. Bats 
have a CD28M228L substitution in the CD28SDYMNM motif.
Potential Unique Signaling Motifs Identified
The two marsupials examined contain a putative TRAF6-binding 
domain in CTLA-4 proteins that was not present in any of the 
placental mammals. We identified a putative ITIM in predicted 
the ECD of dog CD80VKYGDL and a TRAF1/2-binding site in the 
devil CD80ATEEE cytoplasmic domain (Figure  4). Our analysis 
predicted a TRAF6-binding site in the cytoplasmic tail of devil 
CD86GHPKERDEV, a motif not predicted for CD86 in other species 
(Figure 5). Interestingly, the ELM tool predicted a putative ITIM 
domain in the second Ig-like segment of the human CD86IEYDGI 
ECD. To our knowledge, this putative ITIM has not been previ-
ously reported, and thus the potential inhibitory capacity of this 
motif is unknown.
V-Domain Ig Suppressor of T Cell 
Activation
Devil VISTA (PD-1H, C10orf54, Gi24, DD1α, Dies1) is a type-I 
transmembrane protein in the Ig superfamily predicted to be 
33  kDa. The full coding sequence for this gene was previously 
not available in the devil genome (Devil_ref v7.0), but our de 
novo RNA transcriptome assembly uncovered a full coding devil 
VISTA transcript. Devil VISTA shares 60–74% sequence identity 
at the protein level with the other species analyzed here (Figure 6; 
Table 2). The ELM tool predicted a TRAF1/2-binding site in the 
ECD of devil VISTASIQE.
4-1BB
4-1BB (TNFRSF9, CD137) is a predicted 31 kDa member of the 
tumor necrosis factor (TNF) receptor family expressed predomi-
nantly as a type-I transmembrane homodimer (74, 75). 4-1BB 
ligand (4-1BBL, TNFSF9, CD137L) is a TNF family member 
FIGURE 3 | Alignment of CD28 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain 
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. MYPPPY indicates the conserved 
CD80- and CD86-binding site, and SDYMNM and PYAP indicate key phosphorylation sites involved with cell proliferation and activation. The black bar graphs 
below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other species 
is shown in the bottom right corner of the alignment.
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FIGURE 4 | Alignment of CD80 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain 
(TMD), and intracellular domain (ICD) are demarcated with bars. The uppermost devil CD80 sequence is the full-length sequence and the lower devil CD80 is the 
potential secreted CD80 sequence. “d” above the alignment represents predicted disulfide bonds. TRAF indicates a putative TRAF1/2-binding site. The black bar 
graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other 
species is shown in the bottom right corner of the alignment.
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FIGURE 5 | Alignment of CD86 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain 
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. TRAF indicates a putative TRAF6-
binding site. The black bar graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity 
between devils and other species is shown in the bottom right corner of the alignment. See Table 2 for the sequence identity between devils and other species.
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FIGURE 6 | Alignment of V-domain Ig suppressor of T cell activation reference genes for nine species. The predicted signal peptides (SigP), extracellular 
domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide 
bonds and “TRAF” indicates a potential TRAF1/2-binding site. The black bar graphs below the alignment represent the conservation of amino acids across all nine 
species. The percent amino acid sequence identity between devils and other species is shown in the bottom right corner of the alignment.
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of 20  kDa, expressed as a type II transmembrane homotrimer 
(Figure  1). SMART analysis of devil 4-1BB identified two 
TNFR-Cys repeat domains, whereas human 4-1BB contains four 
TNFR-Cys repeats (Figure  7). All cysteine repeats in the four 
human TNFR-Cys domains were conserved in devils, suggesting 
that devil 4-1BB might also contain four TNFR-Cys domains 
despite not being predicted by the SMART program. Indeed, all 
20 cysteine residues involved in disulfide bonds in human 4-1BB 
were also present in devil 4-1BB. Overall sequence identity among 
species compared here ranged from 43 to 75%, with mouse and 
hamster 4-1BB having the lowest percent identities with devil 
4-1BB (Table 2).
We identified a putative inhibitory domain in devil 4-1BBLPYFLK 
based on alignment with a potential inhibitory domain in human 
4-1BBLLYIFK (76, 77). The putative inhibitory domain resembles 
an ITIM domain but lacks the I, L, or V in the terminal amino 
acid position. To date, this potential inhibitory domain has only 
been reported in humans, but several species analyzed here have 
similar motifs. Additionally, mice have a 4-1BBCXCP motif in the 
cytoplasmic domain that facilitates binding of CD4 and CD8 
molecules to p56lck, a protein tyrosine kinase that is important 
for optimal T cell responses (78, 79); of the nine species compared 
here, mice are the only species that have the 4-1BBCXCP sequence. 
Our analysis using the ELM tool predicted two TRAF1/2 ligand-
binding sites (devil 4-1BBTAQEE, 4-1BBPEEE), which align with the 
known TRAF1/2-binding sites in human and mouse 4-1BB (80).
CD47
Human CD47, also known as integrin-associated protein for 
its role in cell adhesion, is a cell surface protein that contains 
five transmembrane segments and a single Ig-like V-type 
domain (81, 82). The most up-to-date gene sequences for devil 
CD47 in Ensembl (ENSSHAT00000014546.1) did not contain 
a full coding sequence (i.e., no start codon) and the GenBank 
(XM_012544496) gene had an extended 5′ region that did not 
align well with other species. Our de novo RNA transcriptome 
assembly uncovered a full coding transcript for CD47 from devil 
PBMCs that aligned well with other species analyzed here. Our 
analysis suggests that the 34 kDa devil CD47 also contains five 
transmembrane segments and a single Ig-like domain (Figure 8). 
The four cysteines needed for the disulfide bonds reported in 
human CD47 are conserved in all species examined here, and 
overall sequence identity across all species compared here ranges 
from 54 to 87% (Table  2). Curiously, the ELM tool predicted 
an ITIM in the devil CD47LKYHVV ECD. All other species except 
bats and hamsters also contain the putative ITIM domains, 
but the ELM tool classified the ITIM as an excluded motif due 
to the putative ITIM being located in ECD of the protein. We 
also identified a putative TRAF2-binding site in the third devil 
intracellular domain of CD47KAVEE that was conserved across all 
species examined here except bats.
SIRP-α
Devil SIRP-α is a predicted 56  kDa protein. Human SIRP-α 
binds to CD47 as either a monomer or a dimer (83, 84) and 
forms three intramolecular disulfide bonds. All six of the 
cysteines that form intramolecular disulfide bonds in humans 
are conserved in devils (Figure S1 in Supplementary Material). 
The percent sequence identity for SIRP-α ranged from 53 to 
69%. Analysis of devil SIRP-α revealed two putative ITIM and 
one ITSM domain. The ITIMITYADL shares 100% identity with 
all species except cattle, and the ITIMLTYADL is 100% conserved 
across all species. The devil ITSMSQTEYASI matches 5/7 amino 
acids with all other species; to our knowledge no ITSM has 
previously been reported in SIRP-α. We identified two poten-
tial SIRP-β1 orthologs in devils (ENSSHAT00000016950, 
XM_012553634.1) that contained ITIM motifs (SIRP-β1VSYNLI) 
in the ECD. The putative SIRP-β1 (ENSSHAT00000016950) 
ITIM aligned with an SIRP-β1VSYNIT sequence in SIRP-α that 
contains the key tyrosine residue for ITIMs but did not contain 
the canonical 3′ I/V/L.
CD200
Devil CD200 is predicted to be a 31 kDa type-I transmembrane 
protein that shares 52–66% sequence identity across the spe-
cies compared here (Figure  9; Table  2). The cysteine residues 
that form intramolecular and intermolecular disulfide bonds 
necessary for binding as either a monomer or homodimer to 
CD200 receptor (CD200R) are 100% conserved across all species 
examined here (Figure 9) (85). Additionally, the Ig-like V-type 
and Ig-like C2-type domains of human and mouse CD200 were 
identified by the SMART tool. Many key motifs, including endo-
cytic sorting signals, and TRAF2, SH2, and SH3 binding motifs, 
are present in all species compared here. Our analysis using ELM 
predicts a potential ITSM only in devil CD200. However, the 
devil CD200TLQE TRAF1/2-binding site and CD200NKTEYVVI ITSM 
are both located in the predicted ECD of devil CD200, so empiri-
cal testing is needed to determine if these are functional sites. 
Although not analyzed in depth here, CD200R and CD200R-like 
proteins were identified in the nine species compared here. The 
primary reference sequence for each species contained the key 
CD200RNPLY motif (86), which has been shown to be a key motif 
for CD200R inhibitory function (87).
TIM-3
TIM-3, also known as T-cell immunoglobulin and mucin 
domain-containing protein 3, hepatitis A virus cellular recep-
tor 2, and CD366, is a surface protein expressed on T  cells, 
Tregs, monocytes, macrophages, and DCs in mice and humans 
[reviewed in Ref. (88)]. The most up-to-date gene sequences 
for devil TIM-3 in Ensembl (ENSSHAT00000018107.1) and 
GenBank (XM_012552117.1) had truncated 3′ region of the 
coding sequence, and the Ensembl gene had an extended 5′ 
region that did not align with other species. Our de novo RNA 
transcriptome assembly uncovered a full coding devil TIM-3 
transcript from devil PBMCs that aligned well with other species 
analyzed here. Analysis of the devil TIM-3 predicted sequence 
suggests that it is a 24 kDa protein with a Ig-like V-type domain 
and mucin domain in the extracellular region of the protein 
(Figure  10). Percent amino acid sequence identity between 
devils and the other eight species analyzed here ranges from 42 
to 53%, which is the lowest identity for any molecule analyzed 
here except for CD80 and CD86 (Table 2). Despite this relatively 
low conservation of protein sequence, many of the key TIM-3 
FIGURE 7 | Alignment of 4-1BB reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain 
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. Two potential TRAF1/2-binding sites 
are demarcated by “TRAF.” “CXCP” marks a motif associated with optimal T cell response in mice, and “LPYFLK” denotes a potential inhibitory domain in devils. 
The black bar graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between 
devils and other species is shown in the bottom right corner of the alignment.
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FIGURE 8 | Alignment of CD47 reference genes for nine species. The predicted signal peptides (SigP), extracellular domains (ECDs), transmembrane domains 
(TMDs), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. “TRAF” indicates a potential 
TRAF1/2-binding site and immunoreceptor tyrosine-based inhibitory motif (ITIM) marks a putative ITIM motif predicted in the ECD. The black bar graphs below the 
alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other species is shown 
in the bottom right corner of the alignment.
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FIGURE 9 | Alignment of CD200 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain 
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. “TRAF” indicates a potential 
TRAF1/2-binding site and “ITSM” represents a putative immunoreceptor tyrosine-based switch motif (ITSM). The black bar graphs below the alignment represent 
the conservation of amino acids across all nine species. The percent amino acid sequence identity between devils and other species is shown in the bottom right 
corner of the alignment.
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FIGURE 10 | Alignment of TIM-3 reference genes for nine species. The predicted signal peptides (SigP), extracellular domain (ECD), transmembrane domain 
(TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted disulfide bonds. “TRAF” indicates a potential 
TRAF1/2-binding site and “MILIBS” demarcates a conserved metal ion-dependent ligand-binding site (MILIBS) found in phosphatidylserine on the surface of 
apoptotic cells. The black bar graphs below the alignment represent the conservation of amino acids across all nine species. The percent amino acid sequence 
identity between devils and other species is shown in the bottom right corner of the alignment.
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features identified in mice and humans appear to be present in 
devil TIM-3.
A unique feature of human TIM-3 is the double cleft which 
facilitates binding to multiple ligands (89, 90). The six cysteines 
that form three intramolecular disulfide bonds in the Ig-like region 
of human TIM-3 (89) are all present in devil TIM-3 (Figure 10), 
suggesting that devil TIM-3 folding and structure might be similar 
to human TIM-3. Analysis of human TIM-3 sequences identified 
five key amino acids for the two ligand-binding clefts; four of the 
five key amino acids were conserved in devil TIM-3. All species 
analyzed here also have two critical tyrosine residues in the 
TIM-3 cytoplasmic domain that align with mouse TIM-3Y256 and 
TIM-3Y263 (Figure 10), which are phosphorylated following liga-
tion by GAL-9 and are associated with increased NFAT/AP-1 and 
NF-κB activity (91). A TIM-3TIEE TRAF1/2-binding site is located 
between these tyrosine residues in all species except for cats, dogs, 
and cattle (Figure 10). Also, mouse TIM-1, TIM-3, and TIM-4 all 
bind to phosphatidylserine on the surface of apoptotic cells via 
a conserved metal ion-dependent ligand-binding site (MILIBS). 
The mouse TIM-3RIQFPGLMND MILIBS motif is 100% conserved in 
cats, dogs, and cattle TIM-3, whereas devils have a phenylalanine 
instead of a methionine in this motif. Whether this TIM-3M114F 
affects phosphatidylserine binding and clearance of apoptotic 
cells in devils is unknown.
Lymphocyte Activation Gene 3
In humans and mice, LAG-3 (CD223) is an inhibitory type-I 
transmembrane protein that is structurally homologous to 
CD4 (92). Human and mice LAG-3 each contain one Ig-like 
V-type and three Ig-like C-type domains, whereas devil LAG-3 
is predicted to be a 54 kDa protein with three Ig-like domains. 
However, a 100 amino acid (LAG3330–429) region downstream of 
the three predicted Ig-like domains could contain a fourth Ig-like 
domain that was not predicted by the SMART prediction tool 
(68, 93). Devil LAG-3 percent sequence identity with the other 
eight species analyzed here ranges from 43 to 73% (Table 2). In 
humans and mice, the LAG-3KIEELE (Figure S2 in Supplementary 
Material) motif in the cytoplasmic domain is critical for down-
stream inhibitory signaling interactions, but this exact sequence 
is not present in the other species analyzed here. The critical 
lysine (LAG-3K468) in this motif is present in devil (LAG-3KAEEME) 
and all other mammals tested here, with the exception of opos-
sums (LAG-3IAEQME).
B7-H4
Devil V-set domain-containing T-cell activation inhibitor 1, 
or more commonly referred to as B7 homolog 4 (B7-H4), is a 
30  kDa type-I membrane protein that contains two Ig-like 
V-type domains in the extracellular region (Figure  11). Devil 
B7-H4 protein shares 87% sequence identity with human B7-H4 
and ranges from 80 to 94% for the other seven species analyzed 
here (Table 2). Based on homology to human and mouse B7-H4 
and analysis of devil B7-H4 using cNLS Mapper (score of 3.4) 
(94, 95), it is likely that devil B7-H4KKRGH contains a bipartite 
nuclear localization signal (NLS). Interestingly, B7-H4 has only 
two amino acids in the cytoplasmic domain when expressed as 
a surface protein.
DISCUSSION
Evolutionary Conservation of Key Protein 
Regions
Despite an estimated 162 million years of evolution since the 
last common ancestor of placental and non-placental mammals, 
most of the checkpoint molecules we analyzed have orthologs in 
Tasmanian devils. Importantly, many of the key signaling motifs 
and ligand-binding sites are highly conserved in the genes ana-
lyzed, particularly cysteine residues for intra- and intermolecular 
disulfide bonds and transmembrane and intracellular tyrosine 
residues for receptor tyrosine kinases. The strong conservation of 
the key protein regions suggests that inhibitory and stimulatory 
function of these molecules, which is relatively well-documented 
in humans and mice, is conserved in devils. Importantly, by fol-
lowing established procedures and focusing on the checkpoint 
molecules that have proven most clinically effective in humans, 
we can rapidly characterize key checkpoint molecules in devils 
and incorporate potent immunomodulatory agents into our DFT 
disease vaccine-development efforts.
The Web of CD28–CTLA-4 Cosignaling 
Pathways
Our analysis shows for the first time that the key CTLA-4MYPPPY 
and CD28MYPPPY are conserved in devils. Given that the MYPPPY 
motif present in chickens facilitates binding to mammalian 
CD80 and that a single leucine for methionine substitution in pig 
CTLA-4LYPPPY is sufficient to disrupt binding of porcine CTLA-4 
to human CD80 (35, 72, 96), the evolutionary conservation of 
CTLA-4MYPPPY and CD28MYPPPY in devils suggests that the com-
petitive binding of CTLA-4 and CD28 for CD80/86 should be 
present in devils.
In addition to the conserved binding motifs, the key 
CD28SDYMNN stimulatory domain (97) and CTLAGVYVKM inhibi-
tory domains are also conserved in devils, suggesting that the 
complementary stimulatory and inhibitory functions of CD28 
and CTLA-4 are present. The CTLA-4GVYVKM motif, in association 
with T-cell receptor-interacting molecule (TRIM), regulates sur-
face expression of CTLA-4 (98). The TRIM-mediated recycling 
of CTLA-4 from the surface provides the means for cell-extrinsic 
inhibitory function by trans-endocytosis of CD80/86 (99). By 
trans-endocytosing, or in other words stripping CD80/86 from 
the surface of an opposing cell (i.e., APCs) and degrading the 
CD80/86 molecules in the CTLA-4-expressing cell, the potential 
of costimulation via CD80/86 binding to CD28 is eliminated. 
Whether trans-endocytosis or trogocytosis (100) occurs in 
devils is unknown. It could be readily tested by developing 
CD80 transgenic cell lines that have a fluorescent protein, 
such as green fluorescent protein (GFP), fused to the 3′ tail of 
CD80. Flow cytometric or immunofluorescence observations 
of GFP transferred from the transgenic cell line to the CTLA-4 
expressing cells would demonstrate that this inhibitory pathway 
is conserved in devils.
The complex interactions involving CTLA-4 are further com-
plicated by some anti-CTLA-4 monoclonal antibody effects that 
are mediated through Fc receptor signaling (11, 101, 102). Tregs 
FIGURE 11 | Alignment of V-set domain-containing T-cell activation inhibitor 1 reference genes for nine species. The predicted signal peptides (SigP), 
extracellular domain (ECD), transmembrane domain (TMD), and intracellular domain (ICD) are demarcated with bars. “d” above the alignment represents predicted 
disulfide bonds. NLS indicates a predicted nuclear localization signal. The black bar graphs below the alignment represent the conservation of amino acids across all 
nine species. The percent amino acid sequence identity between devils and other species is show in the bottom right corner of the alignment.
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expressing high levels of CTLA-4 can be killed via antibody-
dependent cell-mediated cytotoxicity, thus reducing the inhibi-
tion of antitumor immunity. This could be a useful tactic for 
increasing T cell responses against neoantigens in DFT cells, but 
little is known about IgG isotypes and Fc receptors in devils (103). 
To our knowledge only a single IgG subclass has been identified 
in marsupials (103), and the number and type of Fc receptors 
are unknown. Investigations into devil isotypes and Fc receptors 
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are needed to aid development of potential monoclonal antibody 
immunotherapies for devils. Additionally, we identified a poten-
tial TRAF1/2-binding site in devil CD80 and a TRAF6-binding 
site in devil CD86. TRAF6 is associated with NF-κB activation 
and production of IL-6 and IL-8, whereas TRAF2 is associated 
with IκB-kinases. The binding site for TRAF2 but not TRAF6 is 
required CD40-mediated antibody class switching (104–106). 
Specific targeting of CD80 or CD86 by monoclonal antibodies 
or soluble ligands could help to determine if additional IgG 
subclasses exist in devils and to understand the potential role of 
IL-6 and IL-8 in immune evasion by DFT cells.
In addition to binding to both CTLA-4 and CD28 in humans 
and mice, CD80 binds to PD-L1 with a greater affinity than to 
CD28, but less than affinity of CD80 for CTLA and PD-L1 for 
PD-1 (107, 108). In humans, overexpression of CD80 blocks 
PD-L1 expression by sequestering PD-L1 in the cytoplasm 
while simultaneously providing costimulation (109). Additional 
pleiotropic effects of CD80 include its ability to stimulate NK cells 
through both CD28-dependent and -independent pathways 
(110–112). As DFT1 cells are poorly immunogenic and do not 
express MHC-I, the ability to stimulate NK  cells using CD80 
could provide immunotherapeutic potential.
Soluble CD80 can also effectively block PD-1:PD-L1 interac-
tions and provide costimulation (113, 114). Interestingly, in 
addition to the full-length devil CD80, we identified a devil CD80 
splice variant that lacks a transmembrane domain (TMD) and 
likely codes for soluble version of this key checkpoint molecule. 
Humans are also known to express soluble CD80 and soluble 
PD-L1, and high plasma levels of PD-L1 are associated with 
poor prognosis in B cell lymphomas (115–117). The anti-PD-L1 
monoclonal antibodies we have previously developed could be 
used to screen devil plasma for soluble PD-L1 and possibly serve 
as a prognostic test for DFT disease.
Devil 4-1BB Function Is Predicted to 
Resemble Human 4-1BB Function
Despite the potential for enhanced immunotherapies targeting 
the 4-1BB/L pathway, actual progress has been slow, in part due 
to differences between mice and humans. 4-1BB costimulation 
in both mice and humans leads to enhanced T  cell-mediated 
immunity, but the effects are contrasting in human and mouse 
NK cells. In mice, 4-1BB stimulation leads to enhanced NK cell 
effector mechanisms, but in humans 4-1BB signaling inhibits 
NK effector activity and reverse signaling through 4-1BBL 
on tumor cells can induce IL-10 and TNF-α (77, 118). This is 
potentially mediated by a putative inhibitory motif 4-1BBLLYIFK in 
the human cytoplasmic domain that resembles an ITIM domain 
(76, 77). Interestingly, devils have a similar putative 4-1BBLPYFLK 
inhibitory domain that includes the key tyrosine residue, but 
opossum 4-1BB does not contain the putative inhibitory motif 
(4-1BBLSFLLQ). Comparative testing of opossum and devil 4-1BB 
should be able to determine the inhibitory capacity of these 
motifs. Devil 4-1BB also contains conserved TRAF1/2-binding 
sites that in humans are necessary for recruiting TRAF1 and 
TRAF2 and inducing expression of pro-survival genes, includ-
ing Bcl-2, Bcl-XL, and Bfl-1 and decreasing expression of Bim, a 
pro-apoptotic molecule (119–121). Altogether, devil 4-1BB has 
key features that more closely resemble human 4-1BB, and thus 
devil 4-1BB might stimulate T cell function but inhibit NK cell 
function.
As expression of 4-1BB on T cells is largely dependent on acti-
vation state, combining agonistic anti-4-1BB immunotherapies 
with stimulatory cytokines presents an opportunity for promot-
ing immune memory. For instance, CD28- or IL-15-mediated 
upregulation of 4-1BB combined with agonistic anti-4-1BB 
monoclonal antibodies or recombinant 4-1BBL could promote 
antigen-independent survival and expansion of memory CD8 
T cells (122, 123); this could be critical for long-term memory 
against repeated exposure to DFT  cells in the wild. Also of 
particular relevance to the DFT disease is that blockade of 
4-1BB:4-1BBL pathways leads to prolonged allograft survival for 
heart (124), skin (124), eye (125), and intestinal (126) tissues in 
other species.
To Eat or Not to Eat: Phagocytic 
Checkpoints
CD47
CD47 functions as an identifier of “self ” tissue and is expressed 
on nearly all human and mouse cells. It has become known as 
the “don’t eat me” signal due to its ability to inhibit phagocytosis 
following ligation of SIRP-α (CD172a) on phagocytic cells 
(i.e., APCs, macrophages) (127). Of particular relevance to trans-
missible cancers, which are both allografts and cancer, CD47 
appears to play a crucial role in transplant tolerance. The potent 
inhibitory signaling capacity of CD47 was clearly demonstrated 
in a xenotransplant model in which phagocytosis of pig cells 
by human macrophages was abrogated by transfecting the pig 
cells with human CD47 (128, 129). Several other studies have 
confirmed the importance of the CD47:SIRP-α interaction in 
graft and xenotransplant tolerance (129–132). Interestingly, the 
intraspecies CD47:SIRP-α interaction and function seems to 
be conserved in most species, but interspecies compatibility of 
CD47:SIRP-α is low (133). This suggests that CD47:SIRP-α bind-
ing could be a barrier to interspecies transmission of tumors. 
The closest extant relatives of devils, the Eastern quoll (Dasyurus 
viverrinus) and spotted-tail quoll (Dasyurus maculatus), are 
also a conservation priority, so understanding the role of CD47 
in preventing interspecies transmission could prove useful for 
conservation of quolls.
DFT1 and DFT2 are not xenotransplants in devils, but the 
CD47:SIRP-α interaction could be a key mechanism of inhibit-
ing phagocytosis and allo-responses against the DFT  cells. 
Interestingly, in rats and mice, CD47 has been implicated in 
myelin phagocytosis through modulation of CD47:SIRP-α 
interactions (134) This is an immune evasion pathway that may 
have been exploited by DFT1, which originated from a Schwann 
cell and expresses high levels of myelin (37). Despite the nearly 
ubiquitous expression of CD47 by all cell types, expression levels 
are highly variable and can be modulated by inflammation 
(135, 136). High levels of CD47 found on many types of human 
cancer, including leukemia (137–139), lymphoma (140), and sev-
eral types of solid tumor cancers (141, 142) and are often associated 
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with poor prognosis. Importantly, blockade of CD47:SIRP-α 
interactions stimulated enhanced antitumor responses in several 
mouse models of human cancer (141, 143, 144), and trials of 
anti-CD47 antagonistic monoclonal antibodies are underway 
in humans. The MYC oncogene transcription factor binds to 
the promotors of both CD47 and PD-L1 and expression of both 
CD47 and PD-L1 can be downregulated by targeting MYC (145), 
presenting an opportunity to simultaneously target both PD-L1 
and CD47.
A drawback of the anti-CD47 monoclonal antibody treatment 
is that CD47 blockade can lead to anemia due to rapid depletion 
of red blood cells. However, this risk could potentially be mini-
mized by injection of anti-CD47 mAbs or SIRP-α fusion proteins 
directly into accessible DFTs (i.e., tumors in the mouth and face) 
(146). In addition to facilitating cancer cell immune evasion, 
CD47 also affects T  cell and NK  cell homeostasis (147, 148). 
CD47 is suggested to facilitate longevity by reducing clearance by 
phagocytes (135). Blockade of CD47 could thus decrease memory 
cell longevity and increase turnover of T cells and NK cells and 
could be detrimental to long-term DFT immunity in wild devils 
that could be re-exposed to DFT.
V-Domain Ig Suppressor of T Cell Activation
In contrast to the “don’t eat me” signal from CD47 ligation, 
VISTA can function as an “eat me” signal via intercellular 
homophilic binding that affects clearance of apoptotic cells and 
immune surveillance by macrophages and T  cells (149, 150). 
VISTA expression is upregulated in response to genotoxic stress 
in a p53-dependent manner, and homophilic VISTA interactions 
both in cis and trans among tumor cells, APCs, and T cells may 
facilitate tumor cell escape from immune surveillance (149). 
No polymorphisms in devil p53 have been reported (151), but 
given the chromosomal rearrangements and greater than 17,000 
somatic mutation reported in DFT1 cells (152, 153), it seems 
probable that p53 would be at least occasionally activated in 
DFT cells and could induce upregulation of tolerogenic VISTA 
signaling.
The tolerogenic role of VISTA in humans and mice and the 
strong conservation of VISTA across the nine species analyzed 
here (only B7-H4 and CTLA-4 were more conserved) sug-
gest that VISTA may play an important evolutionary role in 
maintaining the balance between tolerance and immunity in 
mammals. Despite high sequence identity, the ELM tool unex-
pectedly predicted a putative TRAF1/2 (VISTASIQE) binding site 
in the ECD of devil VISTA. TRAF binding sites are most com-
monly found in TNF receptors, such as CD27, CD40, OX40, 
and 4-1BB.
Interestingly, two independent research groups first identi-
fied VISTA, but each reported contrasting functional effects 
of anti-VISTA monoclonal antibodies. One study reported 
that mouse VISTA inhibited T cell proliferation and cytokine 
production in vitro, that antagonistic anti-VISTA monoclonal 
antibody treatment exacerbated experimental autoimmune 
encephalomyelitis, and that VISTA overexpression on tumor 
cells led to reduced antitumor immunity in mice (154). By 
contrast, a single dose of agonistic anti-VISTA monoclonal 
antibody completely abrogated graft-versus-host disease in a 
partial and complete allogenic hematopoietic cell transplanta-
tion in mice with mismatched MHC between donor and host 
(155). This is of particular relevance to DFT, which in most 
cases likely has mismatched MHC, so blockade of VISTA could 
prove useful for breaking tolerance to DFT cells. In addition to 
the role of VISTA in transplant tolerance, early studies suggest 
that VISTA could play a more general role in immune escape by 
tumor cells. Several groups have independently demonstrated 
that VISTA-deficient mice have enhanced antitumor immu-
nity compared to wild-type mice (156, 157). These effects are 
independent of PD-1 but are amplified in VISTA/PD-1 double 
knockout mice (158).
TIM-3
Like VISTA, TIM-3 plays a role in phagocytosis of apoptotic cells 
and T cell immunity [reviewed in Ref. (88)]. Ligation of TIM-3 
by phosphatidylserine on apoptotic cells induces an “eat me” 
signal (159–161). The interaction of TIM-3 with its coreceptors 
has been associated with diverse functional outcomes, including 
both inhibitory and stimulatory functions. TIM-3 also binds to 
secreted and surface-expressed galectin-9 (GAL-9, LGALS9) 
and negatively regulates Th1 immunity and IFN-γ production 
(162, 163). As DFT1 cells do not naturally express MHC-I or 
PD-L1 but upregulate both MHC-I and PD-L1 in response to 
IFN-γ, the potential role of TIM-3 in IFN-γ production warrants 
further investigation. TIM-3 and PD-1 are often coexpressed on 
exhausted CD8+ T cells (164) in mice and exhausted TILs in mice 
and humans (165–168).
In contrast to the inhibitory function of TIM-3 on adaptive 
T cells, several types of innate immune cells can be activated by 
TIM-3 ligation (169). Ligation of TIM-3 on mouse and human 
DCs promotes secretion of inflammatory cytokines (169). TIM-3 
is upregulated by TGF-β on tumor-associated macrophages 
(TAMs) of the M2 phenotype and ligation of TIM-3 leads to 
increased NF-κB and IL-6 production and is associated with 
reduced survival in human hepatocellular carcinoma (170). 
TIM-3 also binds to the pleiotropic alarmin HMGB1 and sup-
presses antitumor immunity via interfering with the ability of 
HMGB1 to transport tumor-derived DNA to the endosomes 
of DCs (171). As large DFTs often become ulcerated and/or 
necrotic, it will be interesting to see if HMGB1 or other alarmins 
are expressed.
In regard to receptor structure, TIM-3 is unique due to the 
formation of both cis- and trans-heterodimers with carcinoem-
bryonic antigen cell adhesion molecule 1. The cis heterodimeri-
zation is critical for stable surface expression of TIM-3 and its 
inhibitory function (172, 173). Together, the conserved disulfide 
bonds and ligand-binding amino acids, suggest that devil TIM-3 
function might be similar to humans and mice. Several of the most 
widely used cell lines in laboratory research, including Chinese 
hamster ovary cells, Jurkat RMA-S human lymphoma cells, and 
3T3 mouse fibroblast cells, express natural ligands that bind to 
TIM-3 tetramers (89). This presents the opportunity for the use of 
cross-reactive reagents for devils and other non-traditional study 
species, but as a cautionary note, it also has the potential to cause 
confusing results in attempts to understand checkpoint molecule 
interactions.
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Paired Inhibitory and Stimulatory 
Receptors
CD47 binds to several coreceptors, including SIRP-γ, THSB1, 
and THSB2, which induce either activation or inhibition signals 
(174, 175). An additional SIRP-family protein, SIRP-β1, does not 
bind to CD47 and no ligand for SIRP-β1 has been identified to 
date in humans (176). The SIRP-family proteins are hypothesized 
to be paired receptors that have evolved to reduce pathogen 
exploitation of conserved motifs found in inhibitory receptors, 
essentially a decoy target system that facilitates pathogen control. 
Pathogens that trigger inhibitory signals via conserved motifs in 
inhibitory receptors would thus also trigger activation signals 
when exploiting the similar motifs in the activating receptor 
(177, 178). Analysis of devil SIRP-α revealed two predicted cyto-
plasmic ITIM and one ITSM inhibitory domains, suggesting the 
inhibitory capacity of the CD47:SIRP-α interaction is conserved 
in devils and could be an immunotherapy target. The devil 
SIRP-α ITSM was not detected in any other species, so empirical 
testing will be needed to clarify the potential for targeting the 
CD47:SIRP-α pathway in devils.
Like the SIRP-family proteins, members of the CD200R family 
are hypothesized to have evolved as paired activating and inhibi-
tory receptors. Specifically, herpesviruses, cytomegaloviruses, 
pox viruses, and adenoviruses inhibit macrophage activation via 
CD200 mimics that bind to CD200R-family members (179–181). 
In recent years, CD200 has received greater interest as an inhibi-
tory checkpoint molecule associated with antitumor immunity. 
CD200 is expressed on a wide range of tumors, including lym-
phomas (182), myelomas (183), leukemias (184), and gliomas 
(185), and CD200 expression is correlated with expression of 
epithelial cancer stem cell markers on prostate, brain, breast, and 
colon cancers (186, 187).
Expression of CD200 on tumor cells has been associated 
with impaired NK cell function, increased frequencies of Tregs, 
suppression of memory T  cells, decreased CTL activity, and 
induction of tolerance to allografts (184, 188, 189). Interestingly, 
CD200 expression has also been associated with Th2-skewed 
cytokine profiles and prolonged allograft survival (190–193). 
The transplantable EMT6 mouse breast cancer line expresses 
low levels of CD200 in vitro, but upregulates CD200 following 
inoculation into immunocompetent mice (194); this is similar to 
PD-L1, which is often expressed at low levels in vitro, but rapidly 
upregulated in immune active environments. Given the ongoing 
transmission of DFT for at least 20 years, immunohistochemi-
cal analysis of archived DFT tissue samples should determine 
expression levels of CD200 in the tumor microenvironment, and 
understanding this potential inhibitory pathway could help direct 
vaccine-development efforts.
Like devil PD-1, devil CD200 and SIRP-α are predicted to 
contain ITSM domains capable of regulating TCR signal trans-
duction. ITSMs have been reported for both PD-1 and SIRP-α, 
but to our knowledge this is the first report of an ITSM in CD200. 
Interestingly, the CD200 ITSM was predicted only for devils and 
not any of the other eight species analyzed here, although it is 
possible that other isoforms of CD200 exist. There have only 
been a limited number molecules that have been predicted to 
contain ITSMs: BTLA; 2B4 (CD244); Siglec7; Siglec9; SLAMF1 
(CD150); Ly9 (SLAMF3); CD84 (SLAMF5); SLAMF6 (CD352); 
and SLAMF7 (195, 196). Paired inhibitory and stimulatory recep-
tors are hypothesized to have evolved in response to exploitation 
of inhibitory receptors by pathogens. Thus, pathogen motifs 
that utilize the inhibitory receptor will also trigger the stimula-
tory signal, so it is interesting that the three of the families that 
contain ITSMs are also predicted to be paired-receptor families 
(SIRP, CD200, Siglecs). The original ITSM was identified in 
CD150 and was named “switch-motif ” due to its ability to switch 
from recruitment of SHP-2 to SHIP in the presence of SH2D1A 
(17, 197). This flexible switching aspect of the paired receptors 
could be an additional evolved response to exploitation of inhibi-
tory receptors by common pathogens.
The Unexplored Function of ECD ITIMs 
and ITSMs
The short cytoplasmic tail of CD200 and known soluble forms in 
humans suggests that the primary inhibition through CD200 is 
mediated via ligation of CD200Rs. However, as mentioned above 
we identified a potential inhibitory ITSM in the extracellular 
region of CD200NKTEYVVI. Interestingly, our analysis predicted 
putative inhibitory motifs in the extracellular region of several 
checkpoint molecules: devil CD47LKYHVV ITIM near the border of 
the first extracellular and TMDs; devil SIRP-β1VSYNLI extracellular 
ITIM; dog CD80VKYGDL extracellular ITIM; and human CD86IEYDGI 
extracellular ITIM.
To our knowledge, the function of ITIMs and ITSMs has only 
been explored in intracellular regions of checkpoint molecules. 
However, despite most checkpoint molecules being considered 
transmembrane proteins, the majority of checkpoint molecules 
covered in this analysis are only surface expressed in particular 
contexts. For instance, CTLA-4 protein can be detected in the 
cytoplasm prior to T cell activation, but then is transiently moved 
to the cell surface following activation. Trans-endocytosis of 
ITIM-containing CD80 (dog) or CD86 (human) could allow the 
ECD ITIMs to affect intracellular signaling. Also, CD80, CD86, 
CD200, CD47, all of which were identified to contain extracellular 
inhibitory domains, are part of multi-receptor or paired-receptor 
interactions and the potential role of ECD ITIMs and ITSMs may 
have been overlooked. This is potentially an understudied aspect 
of molecular and cellular immunology that warrants further 
investigation.
The Potential for LAG-3 As an Adjuvant
Although human LAG-3 has a higher affinity for MHC-II than 
CD4, the inhibitory effects of LAG-3 in humans and mice 
are thought to be mediated primarily via negative regulation 
of TCR:CD3 signal transduction rather than competition 
for MHC-II binding (198, 199). In addition to binding to 
MHC-II, LAG-3 also binds to C-type lectin domain family 
4 member G (CLEC4G, LSECTin) and galectin 3 (Gal-3, 
LGALS3). In mice, Gal-3 expression can suppress CD8 anti-
tumor responses and expansion of plasmacytoid DCs (200). 
Tumor cell expression of Gal-3 has also been associated with 
poor prognosis in non-small-cell lung cancer (201), Hodgkin 
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lymphoma (202), and acute myeloid leukemia (203), but the 
opposite effect has also been reported for breast (204) and 
gastric (205) cancer.
Of particular interest for devils is the potential for LAG-3 
to facilitate anti-DFT immunity. Immunization of mice with 
LAG-3+ tumor cells, or irradiated tumor cells along with soluble 
LAG-3-Ig resulted in tumor regression or reduced tumor growth 
(206). In addition, soluble LAG-3-Ig binding to MHC-II reliably 
induced DC maturation, which is indicated by upregulation of 
MHC-II, costimulatory molecules CD40, CD80, CD83, CD86, 
and IL-12 and TNF-α cytokines (207, 208). In allogenic bone 
marrow transplant models, LAG-3 blockade abrogates CD8 
T  cell tolerance to tissue transplants (209), which suggests 
that LAG-3 blockade could be a target for inducing CD8 T cell 
responses to allogenic DFT cells. Additionally, because LAG-3 
signaling is bidirectional, DFT expressed Gal-3 could inhibit 
T and NK  cell responses via direct Gal-3:LAG-3 interactions. 
Finally, LAG-3 and PD-1 are coexpressed in exhausted T cells 
in viral infection and on TILs, and blockade of both LAG-3 and 
PD-1 has been demonstrated to have synergistic effects in mouse 
models (33, 210–212). Altogether, there is a strong potential for 
LAG-3 to stimulate anti-DFT immunity due to the potential for 
overexpression of LAG-3 on tumor cells and/or administration 
of soluble LAG-3-Ig to serve as an adjuvant, and to use mono-
clonal antibodies that block LAG-3 on T cells to reduce T cell 
inhibition.
Strong Conservation of B7-H4 Protein 
across All Species
Despite more than a decade of searching, the identity of the 
B7-H4 coreceptor remains unknown. Further complicating the 
functional role of B7-H4 protein is that it is commonly expressed 
in the cytoplasm and nucleus of cancer cells, and nuclear 
localization of B7-H4 is associated with cell cycle progression 
and proliferation of cancer cells (95). B7-H4 is upregulated to the 
cell surface on T and B cells by several mitogens (213, 214) and 
on monocytes, TAMs, and DCs in response to IL-6 and IL-10 
(215, 216).
Despite the receptor for B7-H4 being unknown, the inhibitory 
function of B7-H4 in regard to T cell responses and apoptosis 
has been well-documented (213, 214, 217). Binding of B7-H4-Ig 
to the putative coreceptor inhibits T cell activation, which can be 
abrogated by monoclonal blockade of B7-H4 (213, 214). B7-H4 
protein has been detected on breast, lung, ovarian, prostate, 
renal cell, and uterine endometrioid cancer cells and is associ-
ated with decreased survival [reviewed in Ref. (20, 218)]. The 
high sequence identity of B7-H4 between humans and devils 
(87%) suggests that B7-H4 function might be similar in devils, 
and thus could be used as a prognostic indicator for DFT in 
addition to the potential for anti-B7-H4 monoclonal antibody 
immunotherapy.
BTLA and TIGIT Inhibitory Genes Not 
Detected in Devils
The molecules described above demonstrated strong homol-
ogy to other mammals, but another key inhibitory molecule in 
humans and mice, BTLA4, has not yet been identified in devils. 
Multiple BTLAs have been identified in bony fish (Teleosts), but 
have not been identified in amphibians or aves (24). Our search of 
GenBank and Ensembl and also our de novo assembly of a tran-
scriptome from devil PBMCs failed to identify a BTLA gene and 
full coding sequence for the TIGIT gene in devils. Several TIGIT 
coreceptors are present in the devil genome and three TIGIT 
transcript variants reported in the opossum genome. Given that 
TIGIT expression appears to be tightly regulated in humans and 
mice (219), we believe it likely that a functional TIGIT gene will 
eventually be detected in devils through targeted laboratory 
methods (i.e., RACE PCR).
CONCLUSION
In addition to the highly conserved motifs in several molecules, 
we documented strong conservation of cysteine residues for 
intra- and intermolecular bonds. These remarkable similarities 
suggest that immunotherapies that have revolutionized human 
oncology might be translatable into immunotherapies for the DFT 
disease. The wealth of data on checkpoint molecule expression 
and function in humans should facilitate understanding of the 
key immune evasion pathways employed by the DFTs and allow 
development of vaccines that target these key pathways. However, 
given the general paucity of reagents for non-traditional study 
species, innovative new techniques may be needed to assess the 
potential roles of the putative signaling motifs, and more gener-
ally to assess checkpoint molecule function in species other than 
humans, mice, and rats.
Investigations into the function of checkpoint molecules 
in devils, dogs, and hamsters may provide insight into the 
transmissibility of these tumors and uncover potential immu-
notherapy targets relevant to both human and veterinary 
medicine. Additionally, our analysis has spawned new ques-
tions about the role of inhibitory ITIM and ITSM motifs and 
paired receptors that could be of highly relevant generally—not 
only to human medicine. Further insight into the evolution 
of the immune system might be gained by studying the role 
of checkpoint molecules in natural disease systems, such as 
white-nose syndrome in bats and chytridiomycosis in amphib-
ians. Diversifying immunological studies into non-traditional 
species may facilitate a broader understanding of key immune 
defense pathways and elucidate general principles that are 
unlikely to be found when studying only a small number of 
model organisms.
AUTHOR CONTRIBUTIONS
AF collected, analyzed, and interpreted the data; prepared 
the figures; and wrote the manuscript. NB performed the de 
novo transcriptome assembly, provided intellectual input, and 
provided critical feedback on the manuscript. AL and GW 
provided intellectual input on immunological processes and 
assisted in the drafting of relevant sections of the manuscript. 
JH provided intellectual input into the overarching framework 
of the study, preclinical insight into feasibility of immunothera-
peutically targeting immune checkpoint inhibition in species 
22
Flies et al. Comparative Analysis of Immune Checkpoint Molecules
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 513
REFERENCES
1. Aruffo A, Seed B. Molecular cloning of a CD28 cDNA by a high-efficiency 
COS cell expression system. Proc Natl Acad Sci U S A (1987) 84:8573–7. 
doi:10.1073/pnas.84.23.8573 
2. Linsley PS, Brady W, Grosmaire L, Aruffo A, Damle NK, Ledbetter JA. Binding 
of the B cell activation antigen B7 to CD28 costimulates T cell proliferation 
and interleukin 2 mRNA accumulation. J Exp Med (1991) 173:721–30. 
doi:10.1084/jem.173.3.721 
3. Jenkins MK, Taylor PS, Norton SD, Urdahl KB. CD28 delivers a costimula-
tory signal involved in antigen-specific IL-2 production by human T  cells. 
J Immunol (1991) 147:2461–6. 
4. Janeway CA, Travers P, Walport M, Shlomchik M. Immunobiology: The 
Immune System in Health and Disease. 6th ed. New York, NY: Garland Science 
Publishing (2001).
5. Harding FA, McArthur JG, Gross JA, Raulet DH, Allison JP. CD28-mediated 
signalling co-stimulates murine T cells and prevents induction of anergy in 
T-cell clones. Nature (1992) 356:607–9. doi:10.1038/356607a0 
6. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. 
A new member of the immunoglobulin superfamily – CTLA-4. Nature (1987) 
328:267–70. doi:10.1038/328267a0 
7. Balzano C, Buonavista N, Rouvier E, Golstein P. CTLA-4 and CD28: similar 
proteins, neighbouring genes. Int J Cancer Suppl (1992) 7:28–32. 
8. Stamper CC, Zhang Y, Tobin JF, Erbe DV, Ikemizu S, Davis SJ, et al. Crystal 
structure of the B7-1/CTLA-4 complex that inhibits human immune 
responses. Nature (2001) 410:608–11. doi:10.1038/35069118 
9. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural 
basis for co-stimulation by the human CTLA-4/B7-2 complex. Nature (2001) 
410:604–8. doi:10.1038/35069112 
10. Kvistborg P, Philips D, Kelderman S, Hageman L, Ottensmeier C, Joseph-
Pietras D, et  al. Anti-CTLA-4 therapy broadens the melanoma-reactive 
CD8+ T  cell response. Sci Transl Med (2014) 6:254ra128. doi:10.1126/
scitranslmed.3008918 
11. Twyman-Saint Victor C, Rech AJ, Maity A, Rengan R, Pauken KE, Stelekati E, 
et  al. Radiation and dual checkpoint blockade activate non-redundant 
immune mechanisms in cancer. Nature (2015) 520:373–7. doi:10.1038/
nature14292 
12. Ribas A, Kefford R, Marshall MA, Punt CJA, Haanen JB, Marmol M, et al. Phase 
III randomized clinical trial comparing tremelimumab with standard-of- 
care chemotherapy in patients with advanced melanoma. J Clin Oncol (2013) 
31:616–22. doi:10.1200/JCO.2012.44.6112 
13. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, 
et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 
369:122–33. doi:10.1056/NEJMoa1302369 
14. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, et al. 
Combined nivolumab and ipilimumab or monotherapy in untreated mela-
noma. N Engl J Med (2015) 373:23–34. doi:10.1056/NEJMoa1504030 
15. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, 
et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. 
N Engl J Med (2015) 372:2006–17. doi:10.1056/NEJMoa1414428 
16. Chatterjee P, Patsoukis N, Freeman GJ, Boussiotis VA. Distinct roles of PD-1 
ITSM and ITIM in regulating interactions with SHP-2, ZAP-70 and Lck, and 
PD-1-mediated inhibitory function. Blood (2013) 122:191. 
17. Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 
associate with immunoreceptor tyrosine-based switch motif of programmed 
death 1 upon primary human T cell stimulation, but only receptor ligation pre-
vents T cell activation. J Immunol (2004) 173:945–54. doi:10.4049/jimmunol. 
173.2.945 
18. Sheppard KA, Fitz LJ, Lee JM, Benander C, George JA, Wooters J, et al. PD-1 
inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta 
signalosome and downstream signaling to PKCtheta. FEBS Lett (2004) 574: 
37–41. doi:10.1016/j.febslet.2004.07.083 
19. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous 
antiapoptotic receptor on cancer cells. Blood (2008) 111:3635–43. doi:10.1182/
blood-2007-11-123141 
20. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenviron-
ment. Nat Rev Immunol (2008) 8:467–77. doi:10.1038/nri2326 
21. Tseng SY, Otsuji M, Gorski K, Huang X, Slansky JE, Pai SI, et al. B7-DC, a new 
dendritic cell molecule with potent costimulatory properties for T cells. J Exp 
Med (2001) 193:839–46. doi:10.1084/jem.193.7.839 
22. Xiao Y, Yu S, Zhu B, Bedoret D, Bu X, Francisco LM, et al. RGMb is a novel 
binding partner for PD-L2 and its engagement with PD-L2 promotes respira-
tory tolerance. J Exp Med (2014) 211:943–59. doi:10.1084/jem.20130790 
23. Hansen JD, Du Pasquier L, Lefranc MP, Lopez V, Benmansour A, Boudinot P. 
The B7 family of immunoregulatory receptors: a comparative and evolu-
tionary perspective. Mol Immunol (2009) 46:457–72. doi:10.1016/j.molimm. 
2008.10.007 
24. Bernard D, Hansen JD, Du Pasquier L, Lefranc MP, Benmansour A, Boudinot P. 
Costimulatory receptors in jawed vertebrates: conserved CD28, odd CTLA4 
and multiple BTLAs. Dev Comp Immunol (2007) 31:255–71. doi:10.1016/j.
dci.2006.06.003 
25. Esch KJ, Juelsgaard R, Martinez PA, Jones DE, Petersen CA. Programmed death 
1-mediated T cell exhaustion during visceral leishmaniasis impairs phagocyte 
function. J Immunol (2013) 191(11):5542–50. doi:10.4049/jimmunol.1301810 
26. Maekawa N, Konnai S, Ikebuchi R, Okagawa T, Adachi M, Takagi S, et  al. 
Expression of PD-L1 on canine tumor cells and enhancement of IFN-g pro-
duction from tumor-infiltrating cells by PD-L1 blockade. PLoS One (2014) 
9:e98415. doi:10.1371/journal.pone.0098415 
27. Hartley G, Faulhaber E, Caldwell A, Coy J, Kurihara J, Guth A, et al. Immune 
regulation of canine tumour and macrophage PD-L1 expression. Vet Comp 
Oncol (2016). doi:10.1111/vco.12197 
28. Regan D, Guth A, Coy J, Dow S. Cancer immunotherapy in veterinary 
medicine: current options and new developments. Vet J (2015) 207:1–9. 
doi:10.1016/j.tvjl.2015.10.008 
other than humans and mice, and critical detailed review of the 
manuscript.
ACKNOWLEDGMENTS
The authors thank David Gearing and Sam Busfield (Nexvet 
Australia Pty. Ltd.) for critical review of the manuscript. The 
authors also would like to thank Alexander Kreiss, Amanda 
Patchett, Cesar Tovar, Georgina Kalodimos, Jocelyn Darby, 
Patrick Lennard, Chrissie Ong, and Ruth Pye for assistance in 
the lab and comments on research and/or manuscript, Elizabeth 
Murchison for advice in regard to the devil genome, Jac 
Charlesworth for help with data archiving, and Emily Flies for her 
ongoing research advice. The authors wish to thank Ginny Ralph 
and DPIPWE devil keepers who provided care for the devils used 
in these experiments.
FUNDING
Research support was provided by the Australian Research 
Council (ARC Linkage grant # LP0989727 and ARC Discovery 
grant # DP130100715) to GW, Morris Animal Foundation (# 
D14ZO-410), Sansom Institute Small Grants Scheme, University 
of Tasmania Foundation Dr Eric Guiler Tasmanian Devil Research 
Grant through funds raised by the Save the Tasmanian Devil 
Appeal (2013, 2015), and Entrepreneurs’ Programme—Research 
Connections grant with Nexvet Australia Pty. Ltd. (RC50680) to AF.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2017.00513/
full#supplementary-material.
23
Flies et al. Comparative Analysis of Immune Checkpoint Molecules
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 513
29. Khatlani TS, Ma Z, Okuda M, Onishi T. Molecular cloning and sequencing 
of canine T-cell costimulatory molecule (CD28). Vet Immunol Immunopathol 
(2001) 78:341–8. doi:10.1016/S0165-2427(01)00238-0 
30. Shosu K, Sakurai M, Inoue K, Nakagawa T, Sakai H, Morimoto M, et  al. 
Programmed cell death ligand 1 expression in canine cancer. In Vivo (2016) 
30:195–204. 
31. Folkl A, Wen X, Kuczynski E, Clark ME, Bienzle D. Feline programmed death 
and its ligand: characterization and changes with feline immunodeficiency 
virus infection. Vet Immunol Immunopathol (2010) 134:107–14. doi:10.1016/ 
j.vetimm.2009.10.019 
32. Ikebuchi R, Konnai S, Shirai T, Sunden Y, Murata S, Onuma M, et al. Increase 
of cells expressing PD-L1 in bovine leukemia virus infection and enhancement 
of anti-viral immune responses in vitro via PD-L1 blockade. Vet Res (2011) 
42:103–17. doi:10.1186/1297-9716-42-103 
33. Okagawa T, Konnai S, Deringer JR, Ueti MW, Scoles GA, Murata S, et  al. 
Cooperation of PD-1 and LAG-3 contributes to T-cell exhaustion in 
Anaplasma marginale-infected cattle. Infect Immun (2016) 84:2779–90. 
doi:10.1128/IAI.00278-16 
34. Ikebuchi R, Konnai S, Okagawa T, Yokoyama K, Nakajima C, Suzuki Y, et al. 
Blockade of bovine PD-1 increases T cell function and inhibits bovine leuke-
mia virus expression in B cells in vitro. Vet Res (2013) 44:1–14. doi:10.1186/ 
1297-9716-44-59 
35. Parsons KR, Young JR, Collins BA, Howard CJ. Cattle CTLA-4, CD28 
and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. 
Immunogenetics (1996) 43:388–91. doi:10.1007/s002510050080 
36. Pearse A-M, Swift K. Allograft theory: transmission of devil facial-tumour 
disease. Nature (2006) 439:549. doi:10.1038/439549a 
37. Murchison EP, Tovar C, Hsu A, Bender HS, Kheradpour P, Rebbeck CA, et al. 
The Tasmanian devil transcriptome reveals Schwann cell origins of a clonally 
transmissible cancer. Science (2010) 327:84–7. doi:10.1126/science.1180616 
38. Murgia C, Pritchard JK, Kim SY, Fassati A, Weiss RA. Clonal origin and 
evolution of a transmissible cancer. Cell (2006) 126:477–87. doi:10.1016/j.cell. 
2006.05.051 
39. vonHoldt BM, Ostrander EA. The singular history of a canine transmissible 
tumor. Cell (2006) 126:445–7. doi:10.1016/j.cell.2006.07.016 
40. Ashbel R. Spontaneous transmissible tumours in the Syrian hamster. Nature 
(1945) 155:607–607. doi:10.1038/155607b0 
41. Brindley DC, Banfield WG. A contagious tumor of the hamster. J Natl Cancer 
Inst (1961) 26:949–57. doi:10.1093/jnci/26.4.949 
42. Metzger MJ, Villalba A, Carballal MJ, Iglesias D, Sherry J, Reinisch C, et al. 
Widespread transmission of independent cancer lineages within multiple 
bivalve species. Nature (2016) 534:705–9. doi:10.1038/nature18599 
43. Metzger MJ, Reinisch C, Sherry J, Goff SP. Horizontal transmission of clonal 
cancer cells causes leukemia in soft-shell clams. Cell (2015) 161:255–63. 
doi:10.1016/j.cell.2015.02.042 
44. Pye RJ, Pemberton D, Tovar C, Tubio JMC, Dun KA, Fox S, et al. A second 
transmissible cancer in Tasmanian devils. Proc Natl Acad Sci U S A (2016) 
113:201519691. doi:10.1073/pnas.1519691113 
45. Siddle HV, Kreiss A, Tovar C, Yuen CK, Cheng Y, Belov K, et al. Reversible 
epigenetic down-regulation of MHC molecules by devil facial tumour disease 
illustrates immune escape by a contagious cancer. Proc Natl Acad Sci U S A 
(2013) 110:5103–8. doi:10.1073/pnas.1219920110 
46. Ljunggren HG, Karre K. In search of the missing self: MHC molecules and 
NK cell recognition. Immunol Today (1990) 11:237–44. 
47. Brown GK, Kreiss A, Lyons AB, Woods GM. Natural killer cell mediated 
cytotoxic responses in the Tasmanian devil. PLoS One (2011) 6:e24475. 
doi:10.1371/journal.pone.0024475 
48. Brown GK, Tovar C, Cooray AA, Kreiss A, Darby J, Murphy JM, et al. Mitogen-
activated Tasmanian devil blood mononuclear cells kill devil facial tumour 
disease cells. Immunol Cell Biol (2016) 94:673–9. doi:10.1038/icb.2016.38 
49. Van Der Kraan LE, Wong ESW, Lo N, Ujvari B, Belov K. Identification of 
natural killer cell receptor genes in the genome of the marsupial Tasmanian 
devil (Sarcophilus harrisii). Immunogenetics (2013) 65:25–35. doi:10.1007/
s00251-012-0643-z 
50. Pye R, Hamede R, Siddle HV, Caldwell A, Knowles GW, Swift K, et  al. 
Demonstration of immune responses against devil facial tumour disease 
in wild Tasmanian devils. Biol Lett (2016) 12:20160553. doi:10.1098/
rsbl.2016.0553 
51. Tovar C, Pye RJ, Kreiss A, Cheng Y, Brown GK, Darby J, et  al. Regression 
of devil facial tumour disease following immunotherapy in immunised Tas-
manian devils. Sci Rep (2017) 7:43827. doi:10.1038/srep43827 
52. Flies AS, Lyons AB, Corcoran LM, Papenfuss AT, Murphy JM, Knowles GW, 
et al. PD-L1 is not constitutively expressed on Tasmanian devil facial tumor 
cells but is strongly upregulated in response to IFN-γ and can be expressed 
in the tumor microenvironment. Front Immunol (2016) 7:581. doi:10.3389/
fimmu.2016.00581 
53. Aken BL, Achuthan P, Akanni W, Amode MR, Bernsdorff F, Bhai J, et  al. 
Ensembl 2017. Nucleic Acids Res (2017) 45:D635–42. doi:10.1093/nar/
gkw1104 
54. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment 
search tool. J Mol Biol (1990) 215:403–10. doi:10.1016/S0022-2836(05) 
80360-2 
55. Patchett AL, Latham R, Brettingham-Moore KH, Tovar C, Lyons AB, 
Woods GM. Toll-like receptor signaling is functional in immune cells of 
the endangered Tasmanian devil. Dev Comp Immunol (2015) 53:123–33. 
doi:10.1016/j.dci.2015.07.003 
56. Andrews S, Babraham B. FastQC A Quality Control Tool for High Throughput 
Sequence Data. (2010). Available from: http://www.bioinformatics.babraham.
ac.uk/projects/fastqc/
57. Grabherr MG, Haas BJ, Yassour M, Levin JZ, Thompson DA, Amit I, et al. 
Full-length transcriptome assembly from RNA-seq data without a reference 
genome. Nat Biotechnol (2011) 29:644–52. doi:10.1038/nbt.1883 
58. Haas BJ, Papanicolaou A, Yassour M, Grabherr M, Blood PD, Bowden J, et al. 
De novo transcript sequence reconstruction from RNA-seq using the Trinity 
platform for reference generation and analysis. Nat Protoc (2013) 8:1494–512. 
doi:10.1038/nprot.2013.084 
59. Zhang Z, Schwartz S, Wagner L, Miller W. A greedy algorithm for aligning DNA 
sequences. J Comput Biol (2000) 7:203–14. doi:10.1089/10665270050081478 
60. James Kent W, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM, 
et al. The human genome browser at UCSC. Genome Res (2002) 12:996–1006. 
doi:10.1101/gr.229102 
61. Knudsen B, Knudsen T, Flensborg M, Sandmann H, Heltzen M, Andersen A, 
et al. CLC Sequence Viewer. (2012). Available from: http://www.clcbio.com
62. Feng DF, Doolittle RF. Progressive sequence alignment as a prerequisite 
to correct phylogenetic trees. J Mol Evol (1987) 25:351–60. doi:10.1007/
BF02603120 
63. Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, et al. Fast, scalable 
generation of high-quality protein multiple sequence alignments using clustal 
omega. Mol Syst Biol (2011) 7:539. doi:10.1038/msb.2011.75 
64. Goodsell DS. Representing structural information with RasMol. In: Baxevanis 
AD, editor. Current Protocols in Bioinformatics. Hoboken, NJ: John Wiley and 
Sons, Inc. (2005). p. 5.4.1–5.4.23. 
65. Gasteiger E, Gattiker A, Hoogland C, Ivanyi I, Appel RD, Bairoch A. ExPASy: 
the proteomics server for in-depth protein knowledge and analysis. Nucleic 
Acids Res (2003) 31:3784–8. doi:10.1093/nar/gkg563 
66. Dinkel H, Van Roey K, Michael S, Davey NE, Weatheritt RJ, Born D, et al. The 
eukaryotic linear motif resource ELM: 10 years and counting. Nucleic Acids 
Res (2014) 42:D259–66. doi:10.1093/nar/gkt1047 
67. Käll L, Krogh A, Sonnhammer ELL. Advantages of combined transmembrane 
topology and signal peptide prediction – the Phobius web server. Nucleic Acids 
Res (2007) 35:W429–32. doi:10.1093/nar/gkm256 
68. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular archi-
tecture research tool: identification of signaling domains. Proc Natl Acad Sci 
U S A (1998) 95:5857–64. doi:10.1073/pnas.95.11.5857 
69. Petersen TN, Brunak S, von Heijne G, Nielsen H. SignalP 4.0: discriminating 
signal peptides from transmembrane regions. Nat Methods (2011) 8:785–6. 
doi:10.1038/nmeth.1701 
70. The UniProt Consortium. UniProt: a hub for protein information. Nucleic 
Acids Res (2014) 43:D204–12. doi:10.1093/nar/gku989 
71. Metzler WJ, Bajorath J, Fenderson W, Shaw SY, Constantine KL, Naemura J, 
et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 
binding site conserved in CD28. Nat Struct Biol (1997) 4:527–31. doi:10.1038/
nsb0797-527 
72. Vaughan AN, Malde P, Rogers NJ, Jackson IM, Lechler RI, Dorling A. Porcine 
CTLA4-Ig lacks a MYPPPY motif, binds inefficiently to human B7 and 
specifically suppresses human CD4+ T cell responses costimulated by pig but 
24
Flies et al. Comparative Analysis of Immune Checkpoint Molecules
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 513
not human B7. J Immunol (2000) 165:3175–81. doi:10.4049/jimmunol.165.6. 
3175 
73. Chen L, Flies DB. Molecular mechanisms of T  cell co-stimulation and co- 
inhibition. Nat Rev Immunol (2013) 13:227–42. doi:10.1038/nri3405 
74. Schwarz H, Tuckwell J, Lotz M. A receptor induced by lymphocyte activation 
(ILA): a new member of the human nerve-growth-factor/tumor-necrosis- 
factor receptor family. Gene (1993) 134:295–8. doi:10.1016/0378- 
1119(93)90110-O 
75. Pollok KE, Kim Y-J, Zhou Z, Hurtado J, Kim KK, Pickard RT, et al. Inducible 
T cell antigen 4-1BB. Analysis of expression and function. J Immunol (1993) 
150:771–81. 
76. Marvel J, Walzer T. CD137 in NK cells. Blood (2010) 115:2987–8. doi:10.1182/
blood-2010-01-261404 
77. Baessler T, Charton JE, Schmiedel BJ, Gru F, Krusch M, Wacker A, et  al. 
CD137 ligand mediates opposite effects in human and mouse NK cells and 
impairs NK-cell reactivity against human acute myeloid leukemia cells. Blood 
(2010) 115:3058–69. doi:10.1182/blood-2009-06-227934.An 
78. Barao I. The TNF receptor-ligands 4-1BB-4-1BBL and GITR-GITRL in NK cell 
responses. Front Immunol (2012) 3:402. doi:10.3389/fimmu.2012.00402 
79. Kim YJ, Pollok KE, Zhou Z, Shaw A, Bohlen JB, Fraser M, et al. Novel T cell 
antigen 4-1BB associates with the protein tyrosine kinase p56lck1. J Immunol 
(1993) 151:1255–62. 
80. Arch RH, Thompson CB. 4-1BB and Ox40 are members of a tumor necrosis 
factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor- 
associated factors and activate nuclear factor kappaB. Mol Cell Biol (1998) 
18:558–65. doi:10.1016/j.bulcan.2015.03.022 
81. Brown E, Hooper L, Ho T, Gresham H. Integrin-associated protein: a 50-kD 
plasma membrane antigen physically and functionally associated with integ-
rins. J Cell Biol (1990) 111:2785–94. doi:10.1083/jcb.111.6.2785 
82. Campbell IG, Freemont PS, Foulkes W, Trowsdale J. An ovarian tumor marker 
with homology to vaccinia virus contains an IgV-like region and multiple 
transmembrane domains advances in brief an ovarian tumor marker with 
homology to vaccinia virus contains an IgV-like region and multiple trans-
membrane domains. Cancer Res (1992) 52:5416–20. 
83. Lee WY, Weber DA, Laur O, Stowell SR, McCall I, Andargachew R, et al. The 
role of cis dimerization of signal regulatory protein α (SIRPα) in binding to 
CD47. J Biol Chem (2010) 285:37953–63. doi:10.1074/jbc.M110.180018 
84. Weiskopf K, Ring AM, Ho CCM, Volkmer J-P, Levin AM, Volkmer AK, et al. 
Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer 
antibodies. Science (2013) 341:88–91. doi:10.1126/science.1238856 
85. Hatherley D, Cherwinski HM, Moshref M, Barclay AN. Recombinant CD200 
protein does not bind activating proteins closely related to CD200 receptor. 
J Immunol (2005) 175:2469–74. doi:10.4049/jimmunol.175.4.2469 
86. Prigent SA, Gullick WJ. Identification of c-erbB-3 binding sites for phospha-
tidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. 
EMBO J (1994) 13:2831–41. 
87. Zhang S, Phillips JH. Identification of tyrosine residues crucial for CD200R-
mediated inhibition of mast cell activation. J Leukoc Biol (2005) 79:363–8. 
doi:10.1189/jlb.0705398 
88. Le Mercier I, Lines JL, Noelle RJ. Beyond CTLA-4 and PD-1, the generation Z 
of negative checkpoint regulators. Front Immunol (2015) 6:418. doi:10.3389/
fimmu.2015.00418 
89. Cao E, Zang X, Ramagopal UA, Mukhopadhaya A, Fedorov A, Fedorov E, 
et al. T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9- 
independent ligand-binding surface. Immunity (2007) 26:311–21. 
doi:10.1016/j.immuni.2007.01.016 
90. Anderson AC, Xiao S, Kuchroo VK. Tim protein structures reveal a unique 
face for ligand binding. Immunity (2007) 26:273–5. doi:10.1016/j.immuni. 
2007.03.004 
91. Lee J, Su EW, Zhu C, Hainline S, Phuah J, Moroco JA, et al. Phosphotyrosine-
dependent coupling of tim-3 to T-cell receptor signaling pathways. Mol Cell 
Biol (2011) 31:3963–74. doi:10.1128/MCB.05297-11 
92. Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S, Genevee C, Viegas-
Pequignot E, et al. LAG-3, a novel lymphocyte activation gene closely related 
to CD4. J Exp Med (1990) 171:1393–405. doi:10.1084/jem.171.5.1393 
93. Letunic I, Doerks T, Bork P. SMART: recent updates, new developments and 
status in 2015. Nucleic Acids Res (2015) 43:D257–60. doi:10.1093/nar/gku949 
94. Kosugi S, Hasebe M, Tomita M, Yanagawa H. Systematic identification of cell 
cycle-dependent yeast nucleocytoplasmic shuttling proteins by prediction of 
composite motifs. Proc Natl Acad Sci U S A (2009) 106:10171–6. doi:10.1073/
pnas.0900604106 
95. Zhang L, Wu H, Lu D, Li G, Sun C, Song H, et al. The costimulatory molecule 
B7-H4 promote tumor progression and cell proliferation through translocat-
ing into nucleus. Oncogene (2013) 32(46):5347–58. doi:10.1038/onc.2012.600 
96. O’Regan MN, Parsons KR, Tregaskes CA, Young JR. A chicken homologue 
of the co-stimulating molecule CD80 which binds to mammalian CTLA-4. 
Immunogenetics (1999) 49:68–71. doi:10.1007/s002510050464 
97. Yin L, Schneider H, Rudd CE. Short cytoplasmic SDYMNM segment of CD28 
is sufficient to convert CTLA-4 to a positive signaling receptor. J Leukoc Biol 
(2003) 73:178–82. doi:10.1189/jlb.0702365 
98. Rudd CE, Taylor A, Schneider H. CD28 and CTLA-4 coreceptor 
expression and signal transduction. Immunol Rev (2009) 229:12–26. 
doi:10.1111/j.1600-065X.2009.00770.x 
99. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, 
et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell 
extrinsic function of CTLA-4. Science (2011) 332:600–3. doi:10.1126/
science.1202947 
100. Gu P, Fang Gao J, D’Souza CA, Kowalczyk A, Chou K-Y, Zhang L. Trogocytosis 
of CD80 and CD86 by induced regulatory T cells. Cell Mol Immunol (2012) 
9:136–46. doi:10.1038/cmi.2011.62 
101. Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, 
et  al. Fc-dependent depletion of tumor-infiltrating regulatory T  cells co- 
defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med 
(2013) 210:1695–710. doi:10.1084/jem.20130579 
102. Bulliard Y, Jolicoeur R, Zhang J, Dranoff G, Wilson NS, Brogdon JL. OX40 
engagement depletes intratumoral Tregs via activating FcγRs, leading to anti-
tumor efficacy. Immunol Cell Biol (2014) 92:475–80. doi:10.1038/icb.2014.26 
103. Sun Y, Wei Z, Li N, Zhao Y. A comparative overview of immunoglobulin 
genes and the generation of their diversity in tetrapods. Dev Comp Immunol 
(2012) 39:103–9. doi:10.1016/j.dci.2012.02.008 
104. Zhang W, Zhang X, Wu X-L, He L-S, Zeng X-F, Crammer AC, et  al. 
Competition between TRAF2 and TRAF6 regulates NF-kappaB activation 
in human B lymphocytes. Chin Med Sci J (2010) 25:1–12. doi:10.1016/
S1001-9294(10)60013-2 
105. Jabara HH, Laouini D, Tsitsikov E, Mizoguchi E, Bhan AK, Castigli E, et al. 
The binding site for TRAF2 and TRAF3 but not for TRAF6 is essential 
for CD40-mediated immunoglobulin class switching. Immunity (2002) 
17:265–76. doi:10.1016/S1074-7613(02)00394-1 
106. Purkerson JM, Smith RS, Pollock SJ, Phipps RP. The TRAF6, but not the 
TRAF2/3, binding domain of CD40 is required for cytokine production 
in human lung fibroblasts. Eur J Immunol (2005) 35:2920–8. doi:10.1002/
eji.200526219 
107. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ. Programmed 
death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to 
inhibit T cell responses. Immunity (2007) 27:111–22. doi:10.1016/j.immuni. 
2007.05.016 
108. Butte MJ, Peña-Cruz V, Kim M-J, Freeman GJ, Sharpe AH. Interaction of 
human PD-L1 and B7-1. Mol Immunol (2008) 45:3567–72. doi:10.1016/j.
molimm.2008.05.014 
109. Haile ST, Bosch JJ, Agu NI, Zeender AM, Somasundaram P, Srivastava MK, 
et al. Tumor cell programmed death ligand 1-mediated T cell suppression 
is overcome by coexpression of CD80. J Immunol (2011) 186:6822–9. 
doi:10.4049/jimmunol.1003682 
110. Wilson JL, Charo J, Martín-Fontecha A, Dellabona P, Casorati G, Chambers BJ, 
et al. NK cell triggering by the human costimulatory molecules CD80 and 
CD86. J Immunol (1999) 163:4207–12. 
111. Chambers BJ, Salcedo M, Ljunggren HG. Triggering of natural killer cells 
by the costimulatory molecule CD80 (B7-1). Immunity (1996) 5:311–7. 
doi:10.1016/S1074-7613(00)80257-5 
112. Kocak E, Abdessalam SF, May K, Martin EW, Liu Y. CD28 is not required 
for B7-mediated costimulation of Nk cell proliferation in response to tumor 
challenge. J Surg Res (2003) 114:301. doi:10.1016/j.jss.2003.08.101 
113. Haile ST, Dalal SP, Clements V, Tamada K, Ostrand-Rosenberg S. Soluble 
CD80 restores T cell activation and overcomes tumor cell programmed death 
ligand 1-mediated immune suppression. J Immunol (2013) 191:2829–36. 
doi:10.4049/jimmunol.1202777 
114. Haile ST, Horn LA, Ostrand-Rosenberg S. A soluble form of CD80 enhances 
antitumor immunity by neutralizing programmed death ligand-1 and 
25
Flies et al. Comparative Analysis of Immune Checkpoint Molecules
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 513
simultaneously providing costimulation. Cancer Immunol Res (2014) 
2:610–5. doi:10.1158/2326-6066.CIR-13-0204 
115. Kakoulidou M, Giscombe R, Zhao X, Lefvert AK, Wang X. Human soluble 
CD80 is generated by alternative splicing, and recombinant soluble CD80 
binds to CD28 and CD152 influencing T-cell activation. Scand J Immunol 
(2007) 66:529–37. doi:10.1111/j.1365-3083.2007.02009.x 
116. Rossille D, Azzaoui I, Feldman AL, Maurer MJ, Labouré G, Parrens M, 
et  al. Soluble programmed death-ligand 1 as a prognostic biomarker for 
overall survival in patients with diffuse large B-cell lymphoma: a replication 
study and combined analysis of 508 patients. Leukemia (2016) 31:988–91. 
doi:10.1038/leu.2016.385 
117. Rossille D, Gressier M, Damotte D, Pangault C, Semana G, Le Gouill S, 
et al. High level of soluble programmed cell death ligand 1 in blood impacts 
overall survival in aggressive diffuse large B-Cell lymphoma: results from a 
French multicenter clinical trial. Leukemia (2014) 28:2367–75. doi:10.1038/
leu.2014.137 
118. Navabi S s, Doroudchi M, Tashnizi AH, Habibagahi M. Natural killer cell func-
tional activity after 4-1BB costimulation. Inflammation (2015) 38:1181–90. 
doi:10.1007/s10753-014-0082-0 
119. Ward-Kavanagh LK, Lin WW, Šedý JR, Ware CF. The TNF receptor super-
family in co-stimulating and co-inhibitory responses. Immunity (2016) 
44:1005–19. doi:10.1016/j.immuni.2016.04.019 
120. Mbanwi AN, Watts TH. Costimulatory TNFR family members in control 
of viral infection: outstanding questions. Semin Immunol (2014) 26:210–9. 
doi:10.1016/j.smim.2014.05.001 
121. Wortzman ME, Clouthier DL, Mcpherson AJ, Lin GHY, Watts TH. The 
contextual role of TNFR family members in CD8+ T-cell control of viral 
infections. Immunol Rev (2013) 255:125–48. doi:10.1111/imr.12086 
122. Zhu Y, Zhu G, Luo L, Flies AS, Chen L. CD137 stimulation delivers an 
antigen-independent growth signal for T lymphocytes with memory pheno-
type. Blood (2007) 109:4882–9. doi:10.1182/blood-2006-10-043463 
123. Pulle G, Vidric M, Watts TH. IL-15-dependent induction of 4-1BB promotes 
antigen-independent CD8 memory T  cell survival. J Immunol (2006) 
176:2739–48. doi:10.4049/jimmunol.176.5.2739 
124. Cho HR, Kwon B, Yagita H, La S, Lee EA, Kim JE, et al. Blockade of 4-1BB 
(CD137)/4-1BB ligand interactions increases allograft survival. Transpl Int 
(2004) 17:351–61. doi:10.1111/j.1432-2277.2004.tb00454.x 
125. Asai T, Choi BK, Kwon PM, Kim WY, Kim JD, Vinay DS, et al. Blockade of the 
4-1BB (CD137)/4-1BBL and/or CD28/CD80/CD86 costimulatory pathways 
promotes corneal allograft survival in mice. Immunology (2007) 121:349–58. 
doi:10.1111/j.1365-2567.2007.02581.x 
126. Wang J, Guo Z, Dong Y, Kim O, Hart J, Adams A, et al. Role of 4-1BB in 
allograft rejection mediated by CD8+ T cells. Am J Transpl (2003) 3:543–51. 
doi:10.1034/j.1600-6143.2003.00088.x 
127. Seiffert BM, Cant C, Chen Z, Rappold I, Brugger W, Kanz L, et al. Human sig-
nal-regulatory protein is expressed on normal, but not on subsets of leukemic 
myeloid cells and mediates cellular adhesion involving its counterreceptor 
CD47. Blood (1999) 94:3633–44. 
128. Ide K, Wang H, Tahara H, Liu J, Wang X, Asahara T, et al. Role for CD47-
SIRPalpha signaling in xenograft rejection by macrophages. Proc Natl Acad 
Sci U S A (2007) 104:5062–6. doi:10.1073/pnas.0609661104 
129. Wang C, Wang H, Ide K, Wang Y, van Rooijen N, Ohdan H, et al. Human 
CD47 expression permits survival of porcine cells in immunodeficient mice 
that express SIRPa capable of binding to human CD47. Cell Transplant (2011) 
20:1915–20. doi:10.3727/096368911X566253 
130. Wang Y, Wang H, Wang S, Fu Y, Yang YG. Survival and function of CD47-
deficient thymic grafts in mice. Xenotransplantation (2010) 17:160–5. 
doi:10.1111/j.1399-3089.2010.00578.x 
131. Wang H, Verhalen J, Madariaga ML, Xiang S, Wang S, Lan P, et al. Attenuation 
of phagocytosis of xenogeneic cells by manipulating CD47. Blood (2007) 
109:836–42. doi:10.1182/blood-2006-04-019794 
132. Waern JM, Yuan Q, Rüdrich U, Becker PD, Schulze K, Strick-Marchand H, 
et al. Ectopic expression of murine CD47 minimizes macrophage rejection of 
human hepatocyte xenografts in immunodeficient mice. Hepatology (2012) 
56:1479–88. doi:10.1002/hep.25816 
133. Subramanian S, Boder ET, Discher DE. Phylogenetic divergence of CD47 
interactions with human signal regulatory protein alpha reveals locus of 
species specificity: implications for the binding site. J Biol Chem (2007) 
282:1805–18. doi:10.1074/jbc.M603923200 
134. Gitik M, Liraz-Zaltsman S, Oldenborg P-A, Reichert F, Rotshenker S. 
Myelin down-regulates myelin phagocytosis by microglia and macrophages 
through interactions between CD47 on myelin and SIRPα (signal regulatory 
protein-α) on phagocytes. J Neuroinflammation (2011) 8:24. doi:10.1186/ 
1742-2094-8-24 
135. Van VQ, Raymond M, Baba N, Rubio M, Wakahara K, Susin SA, et  al. 
CD47high expression on CD4 effectors identifies functional long-lived 
memory T  cell progenitors. J Immunol (2012) 188:4249–55. doi:10.4049/
jimmunol.1102702 
136. Baba N, Van VQ, Wakahara K, Rubio M, Fortin G, Panzini B, et al. CD47 fusion 
protein targets CD172a+ cells in Crohn’s disease and dampens the production 
of IL-1β and TNF. J Exp Med (2013) 210:1251–63. doi:10.1084/jem.20122037 
137. Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, 
et al. Therapeutic antibody targeting of CD47 eliminates human acute lym-
phoblastic leukemia. Cancer Res (2011) 71:1374–84. doi:10.1158/0008-5472.
CAN-10-2238 
138. Jaiswal S, Jamieson CHM, Pang WW, Park CY, Chao MP, Majeti R, et  al. 
CD47 is upregulated on circulating hematopoietic stem cells and leukemia 
cells to avoid phagocytosis. Cell (2009) 138:271–85. doi:10.1016/j.cell.2009. 
05.046 
139. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, et al. CD47 
is an adverse prognostic factor and therapeutic antibody target on human 
acute myeloid leukemia stem cells. Cell (2009) 138:286–99. doi:10.1016/j.cell. 
2009.05.045 
140. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, et al. Anti- 
CD47 antibody synergizes with rituximab to promote phagocytosis and 
eradicate non-Hodgkin lymphoma. Cell (2010) 142:699–713. doi:10.1016/j.
cell.2010.07.044 
141. Willingham SB, Volkmer J-P, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, et al. 
The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic 
target for human solid tumors. Proc Natl Acad Sci U S A (2012) 109:6662–7. 
doi:10.1073/pnas.1121623109 
142. Chao MP, Jaiswal S, Weissman-Tsukamoto R, Alizadeh AA, Gentles AJ, 
Volkmer J, et  al. Calreticulin is the dominant pro-phagocytic signal on 
multiple human cancers and is counterbalanced by CD47. Sci Transl Med 
(2010) 2:63ra94. doi:10.1126/scitranslmed.3001375 
143. Tseng D, Volkmer J-P, Willingham SB, Contreras-Trujillo H, Fathman JW, 
Fernhoff NB, et  al. Anti-CD47 antibody-mediated phagocytosis of cancer 
by macrophages primes an effective antitumor T-cell response. Proc Natl 
Acad Sci U S A (2013) 110:11103–8. doi:10.1073/pnas.1305569110 
144. Chao MP, Tang C, Pachynski RK, Chin R, Majeti R, Weissman IL. Extranodal 
dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited 
by anti-CD47 antibody therapy. Blood (2011) 118:4890–901. doi:10.1182/
blood-2011-02-338020 
145. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, et al. MYC regulates 
the antitumor immune response through CD47 and PD-L1. Science (2016) 
352:227–31. doi:10.1126/science.aac9935 
146. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer 
immunoediting and its three component phases-elimination, equilibrium and 
escape. Curr Opin Immunol (2014) 27:16–25. doi:10.1016/j.coi.2014.01.004 
147. Legrand N, Huntington ND, Nagasawa M, Bakker AQ, Schotte R, Strick-
Marchand H, et  al. Functional CD47/signal regulatory protein alpha 
(SIRP(alpha)) interaction is required for optimal human T- and natural 
killer- (NK) cell homeostasis in  vivo. Proc Natl Acad Sci U S A (2011) 
108:13224–9. doi:10.1073/pnas.1101398108 
148. Sockolosky JT, Dougan M, Ingram JR, Ho CCM, Kauke MJ, Almo SC, et al. 
Durable antitumor responses to CD47 blockade require adaptive immune 
stimulation. Proc Natl Acad Sci U S A (2016) 113:E2646–54. doi:10.1073/
pnas.1604268113 
149. Yoon KW, Byun S, Kwon E, Hwang S-Y, Chu K, Hiraki M, et al. Control of 
signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. 
Science (2015) 349:1261669. doi:10.1126/science.1261669 
150. Muñoz-Fontela C, Mandinova A, Aaronson SA, Lee SW. Emerging roles 
of p53 and other tumour-suppressor genes in immune regulation. Nat Rev 
Immunol (2016) 16:741–50. doi:10.1038/nri.2016.99 
151. Miller W, Hayes VM, Ratan A, Petersen DC, Wittekindt NE, Miller J, et al. 
Genetic diversity and population structure of the endangered marsupial 
Sarcophilus harrisii (Tasmanian devil). Proc Natl Acad Sci U S A (2011) 
108:12348–53. doi:10.1073/pnas.1102838108 
26
Flies et al. Comparative Analysis of Immune Checkpoint Molecules
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 513
152. Deakin JE, Bender HS, Pearse AM, Rens W, O’Brien PCM, Ferguson-Smith MA, 
et al. Genomic restructuring in the Tasmanian devil facial tumour: chromo-
some painting and gene mapping provide clues to evolution of a transmissible 
tumour. PLoS Genet (2012) 8:e1002483. doi:10.1371/journal.pgen.1002483 
153. Murchison EP, Schulz-Trieglaff OB, Ning Z, Alexandrov LB, Bauer MJ, Fu B, 
et al. Genome sequencing and analysis of the Tasmanian devil and its trans-
missible cancer. Cell (2012) 148:780–91. doi:10.1016/j.cell.2011.11.065 
154. Wang L, Rubinstein R, Lines JL, Wasiuk A, Ahonen C, Guo Y, et al. VISTA, a 
novel mouse Ig superfamily ligand that negatively regulates T cell responses. 
J Exp Med (2011) 208:577–92. doi:10.1084/jem.20100619 
155. Flies DB, Wang S, Xu H, Chen L. Cutting edge: a monoclonal antibody 
specific for the programmed death-1 homolog prevents graft-versus-host 
disease in mouse models. J Immunol (2011) 187:1537–41. doi:10.4049/
jimmunol.1100660 
156. Le Mercier I, Chen W, Lines JL, Day M, Li J, Sergent P, et al. VISTA regulates 
the development of protective antitumor immunity. Cancer Res (2014) 74: 
1933–44. doi:10.1158/0008-5472.CAN-13-1506 
157. Flies DB, Han X, Higuchi T, Zheng L, Sun J, Ye JJ, et al. Coinhibitory receptor 
PD-1H preferentially suppresses CD4+ T  cell-mediated immunity. J Clin 
Invest (2014) 124:1966–75. doi:10.1172/JCI74589 
158. Liu J, Yuan Y, Chen W, Putra J, Suriawinata AA, Schenk AD, et al. Immune-
checkpoint proteins VISTA and PD-1 nonredundantly regulate murine 
T-cell responses. Proc Natl Acad Sci U S A (2015) 112:6682–7. doi:10.1073/
pnas.1420370112 
159. Kobayashi N, Karisola P, Peña-Cruz V, Dorfman DM, Jinushi M, Umetsu SE, 
et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate 
uptake of apoptotic cells. Immunity (2007) 27:927–40. doi:10.1016/j.immuni. 
2007.11.011 
160. DeKruyff RH, Bu X, Ballesteros A, Santiago C, Chim Y-LE, Lee H-H, et al.  
T cell/transmembrane, Ig, and mucin-3 allelic variants differentially recognize 
phosphatidylserine and mediate phagocytosis of apoptotic cells. J Immunol  
(2010) 184:1918–30. doi:10.4049/jimmunol.0903059 
161. Savill J, Gregory C. Apoptotic PS to phagocyte TIM-4: eat me. Immunity 
(2007) 27:830–2. doi:10.1016/j.immuni.2007.12.002 
162. Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, et al. Cell surface 
galectin-9 expressing Th cells regulate Th17 and Foxp3+ Treg development 
by galectin-9 secretion. PLoS One (2012) 7:e48574. doi:10.1371/journal.pone. 
0048574 
163. Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, et al. The 
Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat 
Immunol (2005) 6:1245–52. doi:10.1038/ni1271 
164. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, 
et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion 
phenotype in mice with disseminated acute myelogenous leukemia. Blood 
(2011) 117:4501–10. doi:10.1182/blood-2010-10-310425 
165. Gao X, Zhu Y, Li G, Huang H, Zhang G, Wang F, et al. TIM-3 expression char-
acterizes regulatory T cells in tumor tissues and is associated with lung cancer 
progression. PLoS One (2012) 7:e30676. doi:10.1371/journal.pone.0030676 
166. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. 
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore 
anti-tumor immunity. J Exp Med (2010) 207:2187–94. doi:10.1084/jem. 
20100643 
167. Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C, et al.  
Upregulation of TIm-3 and PD-1 expression is associated with tumor anti-
gen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med (2010) 
207:2175–86. doi:10.1084/jem.20100637 
168. Bauer CA, Kim EY, Marangoni F, Carrizosa E, Claudio NM, Mempel TR. 
Dynamic Treg interactions with intratumoral APCs promote local CTL 
dysfunction. J Clin Invest (2014) 124:2425–40. doi:10.1172/JCI66375 
169. Anderson AC, Anderson DE, Bregoli L, Hastings WD, Kassam N, Lei C, 
et  al. Promotion of tissue inflammation by the immune receptor tim-3 
expressed on innate immune cells. Science (2007) 318:1141–3. doi:10.1126/
science.1148536 
170. Yan W, Liu X, Ma H, Zhang H, Song X, Gao L, et  al. Tim-3 fosters HCC 
development by enhancing TGF-β-mediated alternative activation of macro-
phages. Gut (2015) 64:1593–604. doi:10.1136/gutjnl-2014-307671 
171. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, 
et al. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune 
responses through interactions between the receptor TIM-3 and the alarmin 
HMGB1. Nat Immunol (2012) 13:832–42. doi:10.1038/ni.2376 
172. Huang Y-H, Zhu C, Kondo Y, Anderson AC, Gandhi A, Russell A, et  al. 
CEACAM1 regulates TIM-3-mediated tolerance and exhaustion. Nature 
(2015) 517:386–90. doi:10.1038/nature13848 
173. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: co-inhibitory 
receptors with specialized functions in immune regulation. Immunity (2016) 
44:989–1004. doi:10.1016/j.immuni.2016.05.001 
174. Brown EJ, Frazier WA. Integrin-associated protein (CD47) and its ligands. 
Trends Cell Biol (2001) 11:130–5. doi:10.1016/S0962-8924(00)01906-1 
175. Brooke G, Holbrook JD, Brown MH, Barclay AN. Human lymphocytes 
interact directly with CD47 through a novel member of the signal regulatory 
protein (SIRP) family. J Immunol (2004) 173:2562–70. doi:10.4049/jimmunol. 
173.4.2562 
176. Barclay AN, van den Berg TK. The interaction between signal regulatory 
protein alpha (SIRPα) and CD47: structure, function, and therapeutic 
target. Annu Rev Immunol (2014) 32:25–50. doi:10.1146/annurev-immunol- 
032713-120142 
177. Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired 
receptor specificity explained by structures of signal regulatory proteins 
alone and complexed with CD47. Mol Cell (2008) 31:266–77. doi:10.1016/j.
molcel.2008.05.026 
178. Hatherley D, Graham SC, Harlos K, Stuart DI, Barclay AN. Structure of signal 
regulatory protein alpha: a link to antigen receptor evolution. J Biol Chem 
(2009) 284:26613. doi:10.1074/jbc.M109.017566 
179. Foster-Cuevas M, Wright GJ, Puklavec MJ, Brown MH, Barclay AN. Human 
herpesvirus 8 K14 protein mimics CD200 in down-regulating macrophage 
activation through CD200 receptor. J Virol (2004) 78:7667–76. doi:10.1128/
JVI.78.14.7667-7676.2004 
180. Foster-Cuevas M, Westerholt T, Ahmed M, Brown MH, Barclay AN, Voigt S. 
Cytomegalovirus e127 protein interacts with the inhibitory CD200 receptor. 
J Virol (2011) 85:6055–9. doi:10.1128/JVI.00064-11 
181. Voigt S, Sandford GR, Hayward GS, Burns WH. The English strain of rat 
cytomegalovirus (CMV) contains a novel captured CD200 (vOX2) gene and 
a spliced CC chemokine upstream from the major immediate-early region: 
further evidence for a separate evolutionary lineage from that of rat CMV 
Maastricht. J Gen Virol (2005) 86:263–74. doi:10.1099/vir.0.80539-0 
182. Dorfman DM, Shahsafaei A, Alonso MA. Utility of CD200 immunostaining 
in the diagnosis of primary mediastinal large B cell lymphoma: comparison 
with MAL, CD23, and other markers. Mod Pathol (2012) 25:1637–43. 
doi:10.1038/modpathol.2012.129 
183. Tazawa S, Shiozawa E, Homma M, Arai N, Kabasawa N, Kawaguchi Y, 
et al. CD200 expression on plasma cell myeloma cells is associated with the 
efficacies of bortezomib, lenalidomide and thalidomide. J Clin Exp Hematop 
(2015) 55:1–5. doi:10.3960/jslrt.55.121 
184. Coles S, Hills RK, Wang ECY, Burnett AK, Man ST, Darley RL, et  al. 
Expression of CD200 on AML blasts directly suppresses memory T-cell 
function. Leukemia (2012) 26:2148–51. doi:10.1038/leu.2012.77 
185. Moertel CL, Xia J, LaRue R, Waldron NN, Andersen BM, Prins RM, et al. 
CD200 in CNS tumor-induced immunosuppression: the role for CD200 
pathway blockade in targeted immunotherapy. J Immunother cancer (2014) 
2:46. doi:10.1186/s40425-014-0046-9 
186. Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression 
of the toleragenic glycoprotein, CD200, with markers for cancer stem cells. 
Biochem Biophys Res Commun (2007) 364:778–82. doi:10.1016/j.bbrc. 
2007.10.067 
187. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. 
Trends Immunol (2008) 29:464–8. doi:10.1016/j.it.2008.07.005 
188. Coles SJ, Wang ECY, Man S, Hills RK, Burnett AK, Tonks A, et al. CD200 
expression suppresses natural killer cell function and directly inhibits patient 
anti-tumor response in acute myeloid leukemia. Leukemia (2011) 25:792–9. 
doi:10.1038/leu.2011.1 
189. Coles S, Hills RK, Wang ECY, Burnett AK, Man ST, Darley RL, et al. Increased 
CD200 expression in acute myeloid leukemia is linked with an increased 
frequency of FoxP3+ regulatory T cells [Letter]. Leukemia (2012) 26:2146–8. 
doi:10.1038/leu.2012.75 
190. Yu K, Gorczynski RM. Persistence of gene expression profile in 
CD200 transgenic skin allografts is associated with graft survival on 
27
Flies et al. Comparative Analysis of Immune Checkpoint Molecules
Frontiers in Immunology | www.frontiersin.org May 2017 | Volume 8 | Article 513
retransplantation to normal recipients. Transplantation (2012) 94:36–42. 
doi:10.1097/TP.0b013e318257ad5c 
191. Gorczynski L, Chen Z, Hu J, Kai Y, Lei J, Ramakrishna V, et  al. Evidence 
that an OX-2-positive cell can inhibit the stimulation of type 1 cytokine 
production by bone marrow-derived B7-1 (and B7-2)-positive dendritic 
cells. J Immunol (1999) 162:774–81. 
192. Gorczynski RM, Chen Z, Khatri I, Yu K. Graft-infiltrating cells expressing 
a CD200 transgene prolong allogeneic skin graft survival in association 
with local increases in Foxp3 +Treg and mast cells. Transpl Immunol (2011) 
25:187–93. doi:10.1016/j.trim.2011.07.006 
193. Gorczynski RM, Chen Z, He W, Khatri I, Sun Y, Yu K, et al. Expression of a 
CD200 transgene is necessary for induction but not maintenance of tolerance 
to cardiac and skin allografts. J Immunol (2009) 183:1560–8. doi:10.4049/
jimmunol.0900200 
194. Gorczynski RM, Chen Z, Diao J, Khatri I, Wong K, Yu K, et  al. Breast 
cancer cell CD200 expression regulates immune response to EMT6 tumor 
cells in mice. Breast Cancer Res Treat (2010) 123:405–15. doi:10.1007/
s10549-009-0667-8 
195. Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights 
from infections. J Immunol (2012) 188:2957–65. doi:10.4049/jimmunol. 
1100038 
196. Davis SJ, van der Merwe PA. The kinetic-segregation model: TCR triggering 
and beyond. Nat Immunol (2006) 7:803–9. doi:10.1038/ni1369 
197. Shlapatska LM, Mikhalap SV, Berdova AG, Zelensky OM, Yun TJ, 
Nichols KE, et al. CD150 association with either the SH2-containing inositol 
phosphatase or the SH2-containing protein tyrosine phosphatase is regulated 
by the adaptor protein SH2D1A. J Immunol (2001) 166:5480–7. doi:10.4049/
jimmunol.166.9.5480 
198. Hannier S, Triebel F. The MHC class II ligand lymphocyte activation gene-3 
is co-distributed with CD8 and CD3-TCR molecules after their engagement 
by mAb or peptide-MHC class I complexes. Int Immunol (1999) 11:1745–52. 
doi:10.1093/INTIMM/11.11.1745 
199. Hannier S, Tournier M, Bismuth G, Triebel F. CD3/TCR complex-associated 
lymphocyte activation gene-3 molecules inhibit CD3/TCR signaling. J Immu-
nol (1998) 161:4058–65. 
200. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. Galectin-3 
shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 
and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol 
Res (2015) 3:412–23. doi:10.1158/2326-6066.CIR-14-0150 
201. Yoshimura A, Gemma A, Hosoya Y, Komaki E, Hosomi Y, Okano T, et al. 
Increased expression of the LGALS3 (galectin 3) gene in human non-small-
cell lung cancer. Genes Chromosomes Cancer (2003) 37:159–64. doi:10.1002/
gcc.10205 
202. Koh YW, Jung SJ, Park C-S, Yoon DH, Suh C, Huh J. LGALS3 as a prognostic 
factor for classical Hodgkin’s lymphoma. Mod Pathol (2014) 27:1338–44. 
doi:10.1038/modpathol.2014.38 
203. Cheng C, Hou H, Lee M, Liu C, Jhuang J, Lai Y, et al. Prognostic factor for 
overall survival in patients with acute myeloid higher bone marrow LGALS3 
expression is an independent unfavorable prognostic factor for overall 
survival in patients with acute myeloid leukemia. Blood (2013) 121:3172–80. 
doi:10.1182/blood-2012-07-443762 
204. Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, et al. 
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treat-
ment and follow-up. Ann Oncol (2015) 26:v8–30. doi:10.1093/annonc/mdv298 
205. Okada K, Shimura T, Suehiro T, Mochiki E, Kuwano H. Reduced galectin-3 
expression is an indicator of unfavorable prognosis in gastric cancer. 
Anticancer Res (2006) 26:1369–76. 
206. Prigent P, El Mir S, Dréano M, Triebel F. Lymphocyte activation gene-3 
induces tumor regression and antitumor immune responses. Eur J Immunol 
(1999) 29:3867–76. doi:10.1002/(SICI)1521-4141(199912)29:12<3867::AID- 
IMMU3867>3.3.CO;2-5 
207. Andreae S, Piras F, Burdin N, Triebel F. Maturation and activation of den-
dritic cells induced by lymphocyte activation gene-3 (CD223). J Immunol 
(2002) 168:3874–80. doi:10.4049/jimmunol.168.8.3874 
208. Andreae S, Buisson S, Triebel F. MHC class II signal transduction in human 
dendritic cells induced by a natural ligand, the LAG-3 protein (CD223). 
Blood (2003) 102:2130–7. doi:10.1182/blood-2003-01-0273
209. Lucas CL, Workman CJ, Beyaz S, LoCascio S, Zhao G, Vignali DAA, et al. 
LAG-3, TGF-B, and cell-intrinsic PD-1 inhibitory pathways contribute to 
CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-
CD40L. Blood (2011) 117:5532–40. doi:10.1182/blood-2010-11-318675 
210. Grosso JF, Goldberg MV, Getnet D, Bruno TC, Yen H-R, Pyle KJ, et  al. 
Functionally distinct LAG-3 and PD-1 subsets on activated and chronically 
stimulated CD8 T  cells. J Immunol (2009) 182:6659–69. doi:10.4049/
jimmunol.0804211 
211. Grosso JF, Kelleher CC, Harris TJ, Maris CH, Hipkiss EL, De Marzo A, 
et al. LAG-3 regulates CD8+ T cell accumulation and effector function in 
murine self- and tumor-tolerance systems. J Clin Invest (2007) 117:3383–92. 
doi:10.1172/JCI31184 
212. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, et  al. 
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate 
T-cell function to promote tumoral immune escape. Cancer Res (2012) 
72:917–27. doi:10.1158/0008-5472.CAN-11-1620 
213. Sica GL, Choi IH, Zhu G, Tamada K, Wang SD, Tamura H, et al. B7-H4, a 
molecule of the B7 family, negatively regulates T cell immunity. Immunity 
(2003) 18:849–61. doi:10.1016/S1074-7613(03)00152-3 
214. Prasad DVR, Richards S, Mai XM, Dong C. B7S1, a novel B7 family member 
that negatively regulates T  cell activation. Immunity (2003) 18:863–73. 
doi:10.1016/S1074-7613(03)00147-X 
215. Kryczek I, Wei S, Zou L, Zhu G, Mottram P, Xu H, et  al. Cutting 
edge: induction of B7-H4 on APCs through IL-10: novel suppressive 
mode for regulatory T  cells. J Immunol (2006) 177:40–4. doi:10.4049/
jimmunol.177.1.40 
216. Kryczek I, Wei S, Zhu G, Myers L, Mottram P, Cheng P, et al. Relationship 
between B7-H4, regulatory T  cells, and patient outcome in human 
ovarian carcinoma. Cancer Res (2007) 67:8900–5. doi:10.1158/0008-5472.
CAN-07-1866 
217. Choi I-H, Zhu G, Sica GL, Strome SE, Cheville JC, Lau JS, et al. Genomic 
organization and expression analysis of B7-H4, an immune inhibitory 
molecule of the B7 family. J Immunol (2003) 171:4650–4. doi:10.4049/
jimmunol.171.9.4650 
218. Schildberg FA, Klein SR, Freeman GJ, Sharpe AH. Coinhibitory pathways 
in the B7-CD28 ligand-receptor family. Immunity (2016) 44:955–72. 
doi:10.1016/j.immuni.2016.05.002 
219. Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B, et al. The 
surface protein TIGIT suppresses T  cell activation by promoting the gen-
eration of mature immunoregulatory dendritic cells. Nat Immunol (2009) 
10:48–57. doi:10.1038/ni.1674 
Conflict of Interest Statement: AF and GW received funding from an 
Entrepreneurs’ Programme Research Connections grant with Nexvet Australia 
Pty. Ltd. (RC50680). Nexvet is a global clinical-stage biopharmaceutical company 
focused on transforming the therapeutic market for companion animals by devel-
oping and commercializing novel biologic therapies. The other authors declare no 
conflict of interest.
Copyright © 2017 Flies, Blackburn, Lyons, Hayball and Woods. This is an open-access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
